The landscape of somatic mutations in primary prostate adenocarcinoma by Baca, Sylvan Charles
 The landscape of somatic mutations in primary prostate
adenocarcinoma
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation No citation.
Accessed February 19, 2015 1:04:50 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11158271
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA


 
 
 
 
 
 
 
 
 
The landscape of somatic mutations in primary 
prostate adenocarcinoma 
 
 
 
A dissertation presented 
 
 
by 
 
 
Sylvan Charles Baca 
 
 
to 
 
 
The Division of Medical Sciences 
 
 
in partial fulfillment of the requirements 
for the degree of 
Doctor of Philosophy 
in the subject of 
Biological and Biomedical Sciences 
 
 
 
 
 
 
 
 
 
Harvard University 
Cambridge, Massachusetts 
 
April 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2013 Sylvan Charles Baca 
 
All rights reserved. 
 iii 
Advisor: Professor Levi A. Garraway       Sylvan Charles Baca 
 
 
The landscape of somatic mutations in primary prostate 
adenocarcinoma 
 
Abstract 
  
Prostate cancer is the second leading cause of cancer deaths among men. Targeted analyses of 
DNA from prostate cancers have identified recurrent somatic alterations that promote tumor growth and 
survival. Only recently, however, has the comprehensive analysis of cancer genomes become possible 
due to rapid advances in DNA sequencing technology.  
To identify somatic mutations that may drive prostate cancer, we sequenced the protein-coding 
DNA of 112 prostate tumor/normal tissue pairs enriched for aggressive localized disease. We identified 
novel recurrent mutations in several genes, including MED12 and FOXA1. The most frequently mutated 
gene was SPOP, which encodes a ubiquitin ligase complex subunit. Mutations altered the substrate-
binding cleft of the SPOP protein in 6-15% of tumors across multiple independent cohorts. SPOP-mutant 
prostate cancers lacked ETS gene rearrangements and exhibited a distinct pattern of genomic 
alterations, including frequent deletion of the chromatin modifying enzyme gene CHD1. Transcriptome 
profiling of prostate epithelial cells suggested that SPOP mutations and CHD1 loss may promote invasive 
cellular growth and genomic instability, respectively. Thus, SPOP mutations appear to define a new 
molecular subtype of ETS-negative prostate cancer. 
 In order to characterize the landscape of somatic alterations across the entire genome in prostate 
cancer, we also sequenced the full complement of DNA from 57 prostate tumors and matched normal 
tissue. By modeling the genesis of genomic rearrangements, we identified abundant DNA translocations 
and deletions that arise in a highly interdependent manner. This phenomenon, which we term 
“chromoplexy”, frequently accounts for the dysregulation of prostate cancer genes and appears to disrupt 
multiple cancer genes coordinately. Our modeling suggests that chromoplexy may induce considerable 
genomic derangement over relatively few events in prostate cancer and other neoplasms, supporting a 
model of punctuated cancer evolution. Together, the studies described in this thesis point toward novel 
prostate cancer genes and suggest a refined model of prostate tumor evolution.  
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Introduction 
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Introduction  
 
Prostate cancer is the second most common malignancy in men and causes over 250,000 deaths 
each year worldwide (Jemal et al., 2011). At the same time, many men develop indolent prostate tumors 
that remain asymptomatic and do not require treatment. Thus, prostate cancer stands out in both its 
prevalence and markedly variable clinical course. Treatments for advanced prostate cancer center on 
chemotherapy and irradiation as well as hormone ablation therapies that reduce local levels of 
androgens. While these approaches shrink tumors and alleviate symptoms transiently, metastatic tumors 
eventually relapse, and often progress rapidly. On the opposite end of the spectrum, overtreatment of 
benign tumors can cause substantial morbidity from side effects such as impotence and urinary 
incontinence (Daskivich et al., 2011). Therefore, a deeper understanding of the molecular underpinnings 
of aggressive prostate cancer may prove valuable, both to distinguish life-threatening disease from 
benign cases and to elucidate targets for novel therapies.  
Like other neoplasms, prostate cancer is driven in part by alterations that accumulate in the DNA 
of a nascent or growing tumor. Specific mutations of protein-coding genes, gains or losses of gene 
copies, and chromosomal rearrangements promote the growth of prostate cancers and may differentiate 
aggressive versus indolent disease. By comparing DNA sequences from a tumor and matched normal 
tissue from the same individual, one can detect somatic mutations that arose between embryogenesis 
and removal of the tumor. Many studies have searched in a “targeted” fashion for cancer-associated 
mutations (reviewed in (Dong, 2006)); however, only in recent years has massively parallel DNA 
sequencing technology enabled the comprehensive analysis of alterations across the ~3 billion base-pairs 
in a tumor genome (Meyerson et al., 2010).  
The purpose of the research described in this thesis is to leverage recent advances in DNA 
sequencing technology to identify key alterations that arise in prostate tumor development. From these 
data, we aim to glean biological insights about the cellular processes and molecular pathways that drive 
the growth of prostate cancer, including potential nodes for therapeutic intervention. This thesis will 
describe three lines of research to this end. Following an introduction to the field of prostate cancer 
genomics in this chapter, Chapter 2 (based on Barbieri et al., 2012) will describe the sequencing all 
 3	  
protein-coding genes (“exomes”) from 112 prostate tumors. Through statistical analyses designed to 
distinguish “driver” mutations from incidental “passenger” mutations, we identified known and novel 
mediators of prostate tumorigenesis. In Chapter 3 (based on Baca et al., 2013), the analysis of 57 
prostate tumor whole genome sequences will be presented. Sequencing entire genomes (rather than the 
1-2% of DNA that encodes proteins) allowed us to identify chromosomal rearrangements that often arise 
in intergenic DNA and to study how they accumulate. We discuss the implications of these findings for 
tumor evolution and the accumulation of structural alterations in cancer genomes. Lastly, Chapter 4 will 
discuss the effects on gene transcription of cancer-associated alterations in two genes of interest: the 
chromatin-modifying enzyme gene CHD1 and the ubiquitin ligase subunit gene SPOP. 
To contextualize the research described in this thesis, this chapter (based on Baca and 
Garraway, 2012) will survey the understanding of prostate cancer genomics prior to this work. We will 
discuss exemplary somatic mutations in prostate cancer and highlight mutated cellular pathways with 
biological and possibly therapeutic importance. Examples include mutated genes involved in androgen 
signaling, cell cycle regulation, signal transduction and development. We will also discuss genetic 
alterations that may predict the clinical course of disease or response to therapy, as well as the 
challenges posed to genomic biomarker identification by the molecular heterogeneity of prostate tumors.  
 
The mutational spectrum of prostate cancer 
 
All categories of DNA sequence alterations contribute to prostate tumorigenesis, including point 
mutations, small insertions or deletions, copy number changes and chromosomal rearrangements (Figure 
1.1). An overview of each category of alteration and its contribution to prostate cancer biology, is 
presented below. 
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Figure 1.1. Genomic alterations in four high-risk prostate cancers  
Circos plot depiction of rearrangements and copy number alterations in four prostate tumor genomes. 
Intrachromosomal and interchromosomal rearrangements are depicted in green and pink, respectively. 
Somatic copy number alteration is indicated by red (amplification) and blue (deletion). Gleason scores are 
listed, indicating the two most prevalent histologic grades in each tumor. Pathological stage is noted as 
well, where pT3 indicates locally invasive disease. 
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Somatic copy number alterations 
 
Most prostate cancers exhibit somatic copy number alterations (SCNAs), with genomic deletions 
outnumbering amplifications in early stages of disease (Visakorpi et al., 1995). Early studies relied on 
cytogenetics, fluorescence in situ hybridiziation and molecular genetic approaches to map candidate 
cancer genes to regions of SCNA (Brothman et al., 1999). In recent years, comparative genomic 
hybridization and high-density oligonucleotide arrays have allowed high-resolution analysis of SCNAs 
across the genome. Statistical analyses of genome-wide copy number data from panels of tumors have 
pinpointed novel cancer genes in genomic regions that are recurrently deleted or amplified (Beroukhim et 
al., 2007; Robbins et al., 2011; Taylor et al., 2010).  
The extent of SCNA is generally modest in pre-cancerous prostatic intraepithelial neoplasia (PIN), 
but increases along the spectrum from localized adenocarcinoma to metastatic disease (Zitzelsberger et 
al., 2001). Particular recurrent SCNAs are enriched in advanced tumors. For example, tumors that fail 
androgen ablation therapy show frequent amplification of chromosomes 7, 8q and X (Alers et al., 2000; 
Holcomb et al., 2009; Visakorpi et al., 1995). Animal models of prostate cancer indicate that genes in 
these regions, such as the androgen receptor gene (X) and the MYC proto-oncogene (8q), contribute to 
cancer progression, as discussed in detail below.  
 
Point mutations and small insertions-deletions 
 
Relative to structural alterations, recurrent point mutations are less common in primary prostate 
cancers (Kan et al., 2010). Primary tumors generally harbor 1-2 somatic variants per million base pairs – 
far fewer than known carcinogen-driven tumors such as lung cancer or melanoma, but comparable to 
breast, renal, ovarian or microsatellite-stable colon cancers (Berger et al., 2011; Greenman et al., 2007; 
Pleasance et al., 2010a; Pleasance et al., 2010b). While most of these mutations confer no proliferative 
advantage, a handful of recurrent oncogenic mutations have been defined. 
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The reported prevalence of mutations in several known cancer genes varies widely and depends 
on tumor purity, stage, histological grade, and exposure to treatments. For example, RB1, TP53 and 
PTEN are preferentially mutated in locally advanced or metastatic tumors (Cairns et al., 1997b; Eastham 
et al., 1995; Tricoli et al., 1996) while the androgen receptor is mutated only in metastatic or treatment-
resistant disease (Linja and Visakorpi, 2004; Taylor et al., 2010). Ethnicity may influence mutation 
prevalence as well. Activating mutations in KRAS and BRAF occur in ~10% of Asian patients but are rare 
in Caucasian men, perhaps reflecting different environmental or genetic etiologies of cancers in these 
populations (Cho et al., 2006; Konishi et al., 1997; Watanabe et al., 1994).  
Defects in DNA mismatch repair (MMR) machinery have been reported in prostate cancers and 
may accelerate progression to castration-independence (Chen et al., 2001; Dahiya et al., 1997). Large-
scale sequencing studies have recently identified a subset of tumors with markedly elevated rates of point 
mutation (Barbieri et al., 2012; Kumar et al., 2011; Taylor et al., 2010). It remains to be determined 
whether the high levels of mutation in these tumors are caused by MMR deficiency, and whether hyper-
mutated cancers display more clinically aggressive behavior.  
 
Structural rearrangements 
 
The discovery of ETS family gene fusions in roughly half of prostate cancers heralded a novel 
class of alterations in epithelial malignancies as a whole (Tomlins et al., 2005). The most common and 
prototypical ETS fusion places the oncogenic ERG transcription factor under control of the androgen-
regulated TMPRSS2 gene, leading to high expression in the prostate epithelium. Subsequent research 
has identified a host of similar oncogenic fusions, where a proto-oncogene is adjoined to a highly active 
promoter (Kumar-Sinha et al., 2008; Palanisamy et al., 2010; Tomlins et al., 2007). Since mutation or 
amplification of oncogenes is less common in early-stage prostate cancer, genomic rearrangements may 
comprise an important means of cancer gene dysregulation in nascent tumors.  
Complete sequencing of seven prostate cancer genomes has provided further insight into 
chromosomal rearrangements in prostate cancer. Primary tumors harbor an average of roughly 100 
rearrangements, including translocations, deletions, insertions and inversions (Figure 1.1) (Berger et al., 
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2011). Some tumors also display “closed chains” of balanced rearrangements, which appear to arise 
when multiple DNA breaks occur throughout the genome and the resulting fragments are shuffled and 
rejoined to one another. These rearrangements may arise when the affected genetic loci are physically 
proximal to each other, possibly due to co-regulation by transcriptional machinery or nuclear co-
localization in open- or closed-chromatin compartments (Berger et al., 2011; Osborne et al., 2004). 
Consistent with this hypothesis, androgen stimulation can induce physical co-localization of TMPRSS2 
and ERG and permit fusion of these genes de novo via a topoisomerase 2B-mediate mechanism (Haffner 
et al., 2010).  
 The diverse categories of genomic aberrations underscore the need for comprehensive genomic 
analyses both to understand tumor biology, and perhaps to direct targeted therapies on a genotype-
specific basis in the future (Roychowdhury et al., 2011). 
 
Cellular pathways dysregulated by recurrent genomic alterations 
 
Genomic alterations in prostate cancer can increasingly be conceptualized in terms of the 
molecular processes and pathways on which they impinge (Taylor et al., 2010). Mutations in prostate 
cancer may affect signal transduction pathways that regulate growth and proliferation, as well as genes 
involved in the normal development of the prostate. Below, we highlight several themes and pathways 
that provide a framework for understanding genomic alterations in prostate cancer.   
 
PI3K and MAPK signaling 
 
The phosphoinositide 3-kinase (PI3K) pathway is a central mediator of cellular proliferation and 
growth that is aberrantly activated in prostate cancer. In response to pro-proliferative signals, PI3K 
catalyzes the formation of phosphatidylinositol (3,4,5)-triphosphate (PIP3), which recruits Akt to the 
plasma membrane. Upon phospo-activation at the plasma membrane, Akt phosphorylates a wide array of 
substrates that promote proliferation and cell survival.  
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Prostate tumors achieve activation of PI3K signaling most frequently via inactivation of the tumor-
suppressor gene PTEN (Figure 1.2). PTEN encodes a lipid-protein phosphatase that counteracts 
signaling by PI3K via dephosphorylation of PIP3. Loss of heterozygosity at the PTEN locus is found in up 
to 70% of primary prostate cancers and inactivating mutations occur in 5-10% (Barbieri et al., 2012; 
Cairns et al., 1997b; Gray et al., 1998). Inactivation of PTEN is enriched in advanced tumors and 
correlates with decreased cancer-specific survival (McMenamin et al., 1999; Sircar et al., 2009). Pten 
disruption in the mouse prostate collaborates with other tumor-promoting events such as inactivation of 
Tp53 and overexpression of c-Myc or ERG (Chen et al., 2005; Kim et al., 2011a; King et al., 2009).  
Amplification of PIK3CA, which encodes the catalytic subunit of PI3K, occurs in 13% to 39% of 
primary tumors and 50% of castration-resistant tumors (Agell et al., 2011; Edwards et al., 2003; Sun et 
al., 2009). Activating mutations have been observed in ~5% of primary tumors (Barbieri et al., 2012; Sun 
et al., 2009). PIK3CA activation and PTEN loss tend to be mutually exclusive, which suggests functional 
redundancy—although larger sample sizes are needed to assess this relationship robustly (Sun et al., 
2009). Interestingly, PTEN loss and PIK3CA activation co-occur in other neoplasms such as endometrial 
cancer, suggesting that these events may engage disparate oncogenic mechanisms in some contexts 
(Oda et al., 2005). In support of this possibility, oncogenic Akt-independent signaling downstream of 
mutant PIK3CA has been observed in both primary tumors and cancer cell lines (Vasudevan et al., 2009).  
The PI3K pathway may be activated by genomic alterations at additional nodes or dysregulated 
expression of pathway genes (Figure 1.2) (Boormans et al., 2010; Cai et al., 2008; Dong et al., 2006; 
Taylor et al., 2010). Determining whether these lesions predict sensitivity or resistance to PI3K pathway 
inhibitors has become an active area of translational research. 
The mitogen-activated protein kinase (MAPK) pathway also plays a role in prostate cancer 
pathogenesis, especially in advanced and castration-resistant tumors. MAPK pathway activation is 
associated with higher tumor stage and grade and recurrent disease (Gioeli et al., 1999). In the setting of 
castration resistance, PI3K and MAPK signaling are often coordinately dysregulated (Gao et al., 2006; 
Kinkade et al., 2008). Evidence for collaboration between these pathways continues to emerge. For 
instance, PTEN-induced senescence may be overcome by up-regulation of MAPK signaling due to 
overexpression of HER2 (Ahmad et al., 2011).  
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Figure 1.2. Somatic alterations in the PI3K pathway in prostate cancer  
Selected members of the PI3K pathway are depicted, alongside the mechanisms by which they 
are dysregulated in prostate cancer. Putative proto-oncogenes are boxed in red and tumor suppressor 
genes in blue. The transcript expression of most genes in the pathway is altered (Taylor et al., 2010). The 
pathway is frequently activated by deletion of PTEN. In addition, recurrent deletions inactivate the 
FOXO1A gene, which encodes a transcription factor substrate of Akt that mediates PI3K signaling. 
PHLPP1 encodes a phosphatase that dephosphorylates activated Akt, and is frequently co-deleted with 
PTEN in metastatic tumors (Chen et al., 2011). Genomic rearrangements disrupt MAGI2, which encodes 
a scaffolding protein that stabilizes PTEN (Berger et al., 2011; Wu et al., 2000). Although rare, oncogenic 
point mutations in the receptor tyrosine kinase EGFR or AKT1 may activate the pathway upstream or 
downstream of PI3K (Boormans et al., 2010; Cai et al., 2008).) 
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Up-regulation of RAS family members, RAF1 and BRAF, and down-regulation of the counter-
regulatory SPRY1 or SPRY2 genes are commonly observed in prostate cancer metastases (Kwabi-Addo 
et al., 2004; McKie et al., 2005; Taylor et al., 2010). In some cases, expression of RAS, RAF1, and BRAF 
is activated by oncogenic fusion with promoters from highly expressed genes (Palanisamy et al., 2010; 
Wang et al., 2011). Repression of the RAS-GAP gene DAB2IP by EZH2 may activate MAPK signaling 
and drive progression and metastasis (Min et al., 2010). Defining the relevant mechanisms of pathway 
activation in greater detail will likely inform strategies for targeting castration-resistant tumors.  
 
Cell cycle regulatory genes 
 
Several cell cycle regulatory genes are disrupted in prostate cancer. Inactivation of cell cycle 
inhibitors appears to be required to avoid senescence induced by oncogenic signaling and possibly to 
bypass androgen dependence in metastatic or castration resistant tumors.  
The critical cell cycle regulatory genes TP53 and RB1 (which encode p53 and Rb) are commonly 
deleted or mutated in metastatic tumors (Bookstein et al., 1993; Heidenberg et al., 1995; Hyytinen et al., 
1999; Tricoli et al., 1996). p53 activates expression of the p21WAF1 cyclin-dependent kinase inhibitor. 
Inactivation of p53 is necessary to bypass cellular senescence mechanisms that are activated upon loss 
of PTEN (Chen et al., 2005). Likewise, Rb regulates the G1 to S cell cycle phase transition, and RB1 
inactivation is particularly common in castration-resistant tumors (Holcomb et al., 2009; Sharma et al., 
2010).  
Another key cell cycle regulator, CDKN1B, encodes the p27Kip1 cyclin-dependent kinase inhibitor, 
and resides within the 12p13 chromosomal region that is frequently deleted. Low p27Kip1 expression 
correlates with poor pathological prognostic markers (Dreher et al., 2004; Vis et al., 2000). Amplification 
of SKP2, which encodes a ubiquitin ligase that targets p27Kip1 for proteasomal degradation, may also 
serve to inactivate p27Kip1 (Robbins et al., 2011; Taylor et al., 2010). Disruption of Cdkn1b promotes 
prostate carcinogenesis coordinately with hemizygous deletion of Pten, suggesting an interaction 
between p27Kip1 and the PI3K pathway (Di Cristofano et al., 2001). Likewise, the cell cycle regulatory 
function of p27Kip1 induces senescence in PIN lesions driven by Akt1 in mice (Majumder et al., 2008).  
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Developmental and androgen-regulated genes 
 
Normal developmental and androgen-regulated processes appear to be co-opted during 
oncogenesis in the prostate. Several genes that participate in the development and differentiation of the 
prostate epithelium are dysregulated in prostate cancer (Prins and Putz, 2008).  
The androgen receptor regulates cellular proliferation and differentiation in response to hormonal 
signals in the prostate epithelium. While androgen receptor mutations are absent in primary tumors, the 
AR gene is frequently mutated or amplified in metastatic and castration-resistant disease (Koivisto et al., 
1997; Linja and Visakorpi, 2004; Visakorpi et al., 1995). Castration resistant tumors remain dependent on 
the androgen receptor, and overexpression of AR confers castration-resistant growth (Chen et al., 2005). 
AR point mutations allow promiscuous activation by steroid hormones such as estrogens, progestins, 
glucocorticoids and androgen antagonists in 10-30% of refractory cases (Gaddipati et al., 1994; Linja and 
Visakorpi, 2004). Dysregulation of androgen signaling may contribute to localized disease as well: 
mutation and altered expression of several AR-interacting genes including NCOR2, NRIP1, TNK2 and 
EP300 are observed in both primary tumors and metastases (Taylor et al., 2010).  
NKX3-1 encodes a prostate-specific transcription factor that is required for normal development 
of the prostate and is deleted or down-regulated in up to 90% of prostate cancers (Asatiani et al., 2005; 
Emmert-Buck et al., 1995; Vocke et al., 1996). Inactivation of this gene via hemizygous deletion of 
chromosome 8p appears to occur early and can be observed in PIN lesions (Asatiani et al., 2005; 
Emmert-Buck et al., 1995). Nkx3-1-deficient mice exhibit defective branching morphogenesis of the 
prostate gland and develop PIN-like lesions with age (Bhatia-Gaur et al., 1999). In addition, NKX3-1 
appears to protect the differentiated prostate epithelium from oxidative DNA damage (Bowen and 
Gelmann, 2010; Ouyang et al., 2005). Therefore, loss of NKX3-1 may both disrupt terminal differentiation 
and foster the mutational inactivation of collaborating cancer genes such as PTEN (Kim et al., 2002).  
The Wnt pathway regulates embryological development, and its contribution to prostate cancer is 
becoming increasingly recognized (Yardy and Brewster, 2005). Key pathway genes including APC, 
AXIN1 and the β-catenin gene CTNNB1 may be mutated at low frequency (Chesire et al., 2000; Voeller et 
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al., 1998; Yardy et al., 2009). APC undergoes LOH in roughly 20% of primary cancers and promoter CpG 
methylation in up to 90% (Brewster et al., 1994; Phillips et al., 1994; Yegnasubramanian et al., 2004). β-
catenin may promote proliferation through co-activation of AR-mediated transcription (Cronauer et al., 
2005; Truica et al., 2000). Additional mutations in Wnt pathway genes were recently documented in the 
progression to castration-resistant disease (Kumar et al., 2011). More pairs of pre- and post-relapse 
samples should be analyzed to clarify the importance of this pathway in refractory disease.   
 
Genomic heterogeneity of prostate cancer 
 
Prostate cancer is a clinically and genetically heterogeneous disease. Independent cancerous 
foci with distinct morphological features often coexist in a single prostate. The course of disease also 
varies widely: some cancers remain indolent for decades while others rapidly progress to lethality. Distinct 
molecular features appear to underlie the clinical and histological differences. Identifying genomic 
determinants of aggressive disease might improve experimental modeling and stratification of patients 
with intermediate-risk prostate cancer.  
Prostate cancer may arise in multiple foci from independent precursor cells that are driven to 
neoplastic transformation by carcinogenic exposures or genetic predisposition (Andreoiu and Cheng, 
2010). The presence of genomic lesions can vary between foci in a single tumor, including TMPRSS2-
ERG fusion, MYC amplification and TP53 mutation (Jenkins et al., 1997; Mehra et al., 2007; Mirchandani 
et al., 1995). Multiple distinct clones can be identified in a single biopsy (Ruiz et al., 2011), but most 
metastatic prostate cancers appear to originate from a single clone within a primary tumor (Holcomb et 
al., 2009; Liu et al., 2009b; Qian et al., 1995). Among other lesions, subclonal TP53 mutations may define 
cells in the primary tumor with metastatic potential (Mirchandani et al., 1995; Navone et al., 1999). Intra-
tumoral heterogeneity complicates efforts to define prognostic mutations or expression signatures from 
primary tumors, because the primary tumor subclone that gives rise to metastatic disease must be 
adequately sampled (Sboner et al., 2010).  
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Despite the challenges posed by tumor heterogeneity, expression signatures have been 
proposed that delineate histologically aggressive disease or predict outcome independently of clinical 
variables (Febbo, 2009; Glinsky et al., 2004; Singh et al., 2002; True et al., 2006). However, the overlap 
between signatures from independent studies is moderate. Some genomic alterations appear to have 
prognostic value as well. The TMPRSS2-ERG fusion, MYC amplification, and PTEN or p53 deletion 
predict cancer-specific death in at least some patient cohorts (Demichelis et al., 2007; Sato et al., 1999; 
Sircar et al., 2009). In some cases, a mutational signature may underlie expression-based sub-
classifications (Lapointe et al., 2004; Lapointe et al., 2007).  
 
Conclusion 
 
 In summary, the analysis of prostate cancer genomes using targeted sequencing approaches and 
gene copy number profiling has pointed toward molecular pathways and processes that are dysregulated 
in prostate cancers. Disrupted genes include mediators of androgen signaling and prostatic development 
as well as regulators of cell division. Importantly, genomic alterations target both generic cancer-
associated pathways and processes that impinge more specifically on prostate tissue. Therefore, the 
unbiased characterization of prostate cancer genomes through whole-exome and whole-genome 
sequencing may hold promise for the discovery of novel cancer genes that have not previously been 
identified in other cancer types. Along these lines, the following chapters discuss the use of massively 
parallel sequencing to analyze prostate cancer genomes and exomes, building upon the studies reviewed 
here to expand our view of the genomic landscape of prostate cancer.  
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CHAPTER 2 
 
Identification of driver mutations in prostate cancer using 
whole-exome sequencing 
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Stojanov, P., Van Allen, E., Stransky, N., et al. (2012). Exome sequencing identifies recurrent SPOP, 
FOXA1 and MED12 mutations in prostate cancer. Nature Genetics 44, 685-689. 
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Introduction 
 
As described in the previous chapter, copy number alterations and oncogenic rearrangements 
are common in prostate cancer. These events include losses of NKX3.1 (8p21) (Bhatia-Gaur et al., 1999; 
He et al., 1997)
 
and PTEN (10q23) (Cairns et al., 1997a; Li, 1997), gains of the androgen receptor gene 
(AR) (Linja and Visakorpi, 2004; Visakorpi et al., 1995)
 
and fusion of ETS-family transcription factor 
genes with androgen-responsive promoters (Perner et al., 2006; Tomlins et al., 2007; Tomlins et al., 
2005). In contrast, recurrent somatic base-pair substitutions are believed to be less contributory in 
prostate tumorigenesis (Kumar et al., 2011; Taylor et al., 2010),
 
but have not been systematically 
analyzed in large cohorts. To identify somatic mutations that may drive prostate cancer and aid in 
molecular characterization, we sequenced the exomes of 112 tumor/normal pairs enriched for 
characteristics of aggressive localized disease (pathological stage ≥ pT2, Gleason score ≥ 7). Novel 
recurrent mutations were identified in multiple genes, including MED12 and FOXA1. SPOP was the most 
frequently mutated gene, with mutations involving the SPOP substrate binding cleft in 6-15% of tumors 
across multiple independent cohorts. SPOP-mutant prostate cancers lacked ETS rearrangements and 
exhibited a distinct pattern of genomic alterations. Thus, SPOP mutations may define a new molecular 
subtype of prostate cancer. 
 
Whole exome sequencing of 112 primary prostate tumor–normal tissue 
pairs 
 
We performed exome capture followed by paired-end, massively parallel sequencing on DNA 
from 112 prostate adenocarcinomas and matched normal samples. We focused on treatment-naïve 
radical prostatectomy specimens from American and Australian patients that spanned a range of grades, 
stages, and risk of recurrence (Table S2.1; please see Appendix 1: Supplemental tables). The exon 
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capture baits targeted 98.2% of genes in the Consensus CDS database as of November 2010 
(http://www.ncbi.nlm.nih.gov/CCDS). A mean coverage depth of 118x per sample was achieved, with 
89.2% of targets covered at ≥ 20x depth (Table S2.2 and Figure S2.1; please see Appendix 2: 
Supplemental figures). Tumor and normal DNA were also analyzed by Affymetrix SNP 6.0 arrays to 
detect somatic copy number alterations. In addition, transcriptome sequencing (“RNA-Seq”) was 
performed on 22 exome-sequenced tumors and 41 independent samples (Figure S2.2). 
We identified 5,764 somatic mutations that were present in tumor DNA but absent in peripheral 
blood or non-cancerous prostate (Table S2.3). Of these, 997 variants occurred in a single tumor that 
harbored a frame-shift mutation of the mismatch-repair gene MSH6 (Figure S2.3). After excluding this 
highly-mutated sample, the remaining tumors contained a median of 10 silent and 30 non-silent mutations 
(range 10 to 105 total mutations) or ~1.4 per Mb covered (Figure S2.3). Analysis of 229 non-silent 
mutations by mass-spectrometric genotyping validated 95.6% of variants with allelic fraction ≥ 0.2 (C.I. 
92-98%) (Table S2.3). The mutation rate of this cohort exceeded that of seven published prostate tumor 
genomes (0.9 mutations per Mb) (Berger et al., 2011), perhaps because the increased exome sequence 
coverage improved detection of variants present at lower allelic fractions. 
 
Distinct mutational characteristics of tumor subclasses 
 
We investigated whether pathological features corresponded to different mutational spectra. 
Pathologic stage pT3 tumors contained more mutations than pT2 tumors (p = 1.2 x 10-3, rank sum test) 
despite equivalent tumor purity between these classes (Figures S2.4 and S2.5). Substitutions in PTEN 
and PIK3CA were enriched in pT3 tumors (p = 0.011, Fisher’s exact test) (Table S2.4), suggesting that 
these mutations may play a role in disease progression. Consistent with this possibility, activation of the 
PI3-Kinase pathway in mouse models accelerates the progression of prostate cancer (McMenamin et al., 
1999; Trotman et al., 2003). This finding will need to be extended to larger panels of tumors due to the 
relatively small number of PTEN and PIK3CA mutations reported here. Interestingly, the base mutation 
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rate showed no correlation with Gleason score (a histological measure of disease risk) (Figure S2.5), 
indicating that mutational burden does not track uniformly with disease aggressiveness. 
In addition, we noted that the mutational spectrum varied between prostate tumors harboring the 
TMPRSS2-ERG fusion and fusion-negative tumors. TMPRSS2-ERG fusion-positive tumors showed an 
increased proportion of CpG to T transitions (p = 2 x 10-4, Figure S2.5) but did not harbor more mutations 
overall. Since CpG to T transitions can arise from deamination of methylcytosine in cancer, this trend may 
reflect the differential methylation of DNA between ETS fusion-positive and fusion-negative tumors that 
was recently reported (Kim et al., 2011b)
 
or may indicate a distinct mutagenic process in fusion-positive 
tumors. 
 
Significantly mutated genes in prostate cancer 
 
We searched for genes that harbored more non-synonymous mutations than expected by chance 
given gene size, sequence context and the frequency of mutations for each tumor (Figure 2.1A and Table 
S2.5). Twelve genes were enriched for mutations at q-value < 0.1, the majority of which are highly 
expressed at the transcript level in prostate tumors (Figure S2.6). The identification of PIK3CA, TP53 and 
PTEN confirmed that our approach detected alterations known to promote tumorigenesis in prostate 
cancer and other malignancies. We also found evidence of enrichment for mutations in the PTEN 
pathway, cell cycle regulatory machinery, and other gene sets (Table S2.6). 
The most frequently mutated gene was SPOP (13% of cases; Figure 2.1), which encodes the 
substrate-binding subunit of a Cullin-based E3 ubiquitin ligase (Nagai et al., 1997; Zhuang et al., 2009). 
Although isolated SPOP mutations have been reported in prostate cancer (Berger et al., 2011; Kan et al., 
2010), this gene has not been found significantly mutated in any malignancy. Several novel genes not 
previously known to undergo somatic alteration in prostate cancer were enriched for mutations, including 
FOXA1, MED12, THSD7B, SCN11A and ZNF595. The p27Kip1 gene CDKN1B was somatically mutated in 
three samples and deleted in sixteen others (Figure 2.1B). p27Kip1
 
constrains prostate tumor growth in 
mice (Majumder et al., 2008) and harbors a germline prostate cancer risk allele (Kibel et al., 2003), but 
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Figure 2.1. Significantly mutated genes in aggressive primary prostate cancer 
(A) (Top) A cohort of 111 primary prostate tumors is ordered by number of mutations per Mb sequenced. 
(Center) Mutations in significantly mutated genes, colored by the coding consequence of the mutation. 
Each column represents a tumor and each row a gene. (Left) Number and percentage of tumors with 
mutations in a given gene. (Right) The negative log of the q-values for the significance level of mutated 
genes is shown (for all genes with q < 0.1; see Methods).  
(B) Net frequency of gene deletion/amplification across 169 copy number-profiled tumors. Significantly 
mutated genes are indicated. Only autosomal genes with two or more mutations are shown. 
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somatic substitutions have not previously been observed in this cell cycle regulatory protein.  
The Forkhead transcription factor gene FOXA1 harbored nonsilent mutations in 4 of 111 exomes 
and 4 of 41 independent RNA-Seq samples. FOXA1 is required for epithelial cell differentiation in the 
murine prostate (Gao et al., 2005) and promotes cell cycle progression in castration-resistant prostate 
cancer (Zhang et al., 2011). Notably, FOXA1 modulates AR-driven transcription (Gao et al., 2003)
 
and 
activates expression of CDKN1B (Williamson et al., 2006). Mutations strictly affected residues in the 
Forkhead domain that reside near the DNA binding surface (Figure 2.2A and Table S2.5) (Clark et al., 
1993). The clustered nature of these mutations suggests that they may disrupt binding of FOXA1 DNA 
targets. 
Mutations affecting MED12 were observed in 6 out of 111 exomes, with a recurrent F1224L 
mutation in five samples (Figure 2.2B and Table S2.5). MED12 encodes a subunit of the mediator 
complex and the Cyclin-dependent kinase 8 (CDK8) sub-complex that regulates basal and stimulus-
specific transcriptional programs (Donner et al., 2007; Wang et al., 2002; Zhou et al., 2002). Recently, 
MED12 mutations were reported in 70% of uterine leiomyomas (Makinen et al., 2011), benign stromal 
tumors of the smooth muscle lineage. Mutations in prostate cancer affected distinct codons from those in 
leiomyoma and occurred in epithelial cells rather than stroma as determined by laser-capture 
microdissection (LCM) (Supplementary Figure S2.7). Conceivably, MED12 mutations may perturb CDK8-
dependent modulation of transcriptional programs linked to p53 and androgen signaling (Donner et al., 
2007; Wang et al., 2002). 
 
Low-frequency mutations in cancer-associated genes 
 
Multiple genes with established roles in other cancers were mutated at low frequency, including 
IDH1, AKT1 and HRAS (Table S2.5). An analysis of predicted “damaging” mutations (nonsense 
substitutions, frame-shift indels and splice site alterations) in potential tumor suppressor genes expressed 
in prostate tumors identified mutations in APC, PIK3R1 and EPHA7 (Table S2.5). In addition, several 
chromatin-modifying enzymes harbored low-frequency damaging mutations, including MLL1, MLL2,  
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Figure 2.2 Recurrent somatic mutations in FOXA1 and MED12  
(A) Structural analysis of mutations in FOXA1. Mutated residues are mapped to the structure of the 
HNF3γ fork-head domain from coordinate file 1VTN.pdb (www.pdb.org) (Clark et al., 1993) and 
highlighted in red. In both (A) and (B), mutations detected by exome sequencing are depicted (red), as 
are variants from non-overlapping transcriptome sequencing data (blue). FH, Fork-head domain.  
(B) Recurrent MED12 mutations in prostate cancer (red, blue) are distinct from those reported in uterine 
leiomyeoma (shown in black) (Makinen et al., 2011). Domains of MED12 based on sequence content 
depicted based on Zhou et al. (Zhou et al., 2002). Multispecies conservation of the mutated sites is 
shown below the mutation. 
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MLL3, ARID1A, NCOR1 and the histone demethylase gene KDM6A (UTX). Two KDM6A mutations 
involved residues situated within the catalytic Jumonji domain (I1209 and G1212), while a third introduced 
a frame-shift deletion directly N-terminal to this region (Table S2.5). These findings underscore the 
emerging importance of chromatin-modifying genes in prostate cancer (Gao and Alumkal, 2010; Grasso 
et al., 2012). Notably, AR was not mutated in any primary tumor analyzed, consistent with prior studies 
suggesting that mutations in this gene are restricted to metastatic or castration-resistant disease (Linja 
and Visakorpi, 2004; Taylor et al., 2010).  
 
Recurrent mutations alter the substrate binding surface of the SPOP 
ubiquitin ligase complex protein 
 
Although SPOP mutations were originally reported in genomic studies of prostate cancer (Berger 
et al., 2011; Kan et al., 2010), their prevalence and functional relevance remained unknown. We therefore 
sequenced this gene in multiple additional cohorts comprising over 300 primary tumors and metastases 
from the US and Europe. Using RNA-Seq and Sanger sequencing of tumor and matched germline DNA, 
recurrent heterozygous SPOP substitutions were identified in 6 to 13% of primary prostate 
adenocarcinomas (Figures 2.3A and S2.8, Table S2.7). No mutations were identified in 36 benign 
prostate tissue samples, prostate stroma, or 6 common prostate cell lines. SPOP mutations were also 
found in 6 of 41 patients with metastatic disease (14.5%). Thus, SPOP mutations occur at a 6 to 15% 
frequency across localized and advanced prostate tumors. 
All SPOP mutations affected conserved residues in the structurally-defined substrate binding cleft 
(Figures 2.3B and Figure S2.9) (Zhuang et al., 2009). Several recurrently mutated residues exert key 
substrate-interacting roles; moreover, mutation of Y87, W131, and F133 disrupts substrate binding in vitro 
(Zhuang et al., 2009). These results strongly suggest that prostate cancer SPOP mutations are 
biologically consequential. To test this hypothesis, we examined the consequences of mutant SPOP 
protein expression or SPOP knock-down on tumorigenic phenotypes in vitro. Prostate cancer cells  
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Figure 2.3.  Structural and functional studies of recurrent SPOP mutations in prostate cancer  
(A) Positional distribution of somatic mutations in SPOP across the Weill Cornell Medical College 
(WCMC), University of Michigan (UM), Uropath, and University of Washington (UW) prostate tumor 
cohorts.  
(B) Mutated residues in the crystal structure of the SPOP MATH domain bound to substrate (PDB 3IVV). 
(C) Representative images of invasive 22Rv1 and DU145 cells transfected with control and SPOP siRNA 
in Matrigel invasion assays.  
(D) Quantitation of invaded cells transfected with SPOP siRNA.  
(E) Quantitation of invaded DU145 cells transfected with GFP, SPOP wt, and SPOP F133V. 
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transfected with the most common SPOP mutant (F133V) or SPOP siRNA showed increased invasion 
compared to controls (Figures 2.3C-E and S2.10), but cell growth and viability were largely unaffected 
(Figure S2.11). The SPOP-CUL3 complex affects a variety of substrates that impact multiple pathways, 
including hedgehog, JNK, and steroid receptor signaling cascades (Li et al., 2011; Liu et al., 2009a; Wang 
et al., 2002). SPOP undergoes amplification in other malignancies and may be overexpressed in renal 
cell carcinoma (Liu et al., 2009a); however multiple prostate cancer cohorts showed no evidence of 
SPOP amplification or up-regulation (Figure 2.1B, Figure S2.12). Conceivably, prostate cancer-
associated SPOP mutations exert de novo gain of function alterations (e.g., a distinct substrate profile), 
dominant negative effects, or more subtle alterations in substrate specificity. Further studies are 
necessary to determine the specific ubiquitin ligase functions and cellular pathways deregulated by SPOP 
mutation in prostate cancer. 
 
SPOP mutations define a molecular subtype of ETS fusion-negative 
prostate cancer  
 
Strikingly, all exomes with SPOP mutations lacked the TMPRSS2-ERG fusion or other ETS 
rearrangements (Figure 2.4, Figure S2.13), present in roughly 50% of prostate cancers (Mosquera et al., 
2009; Tomlins et al., 2005). This mutually exclusive relationship between SPOP mutation and ERG 
rearrangement (p < 0.001, Fisher’s exact test) was confirmed in evaluable samples across all five cohorts 
tested (Figure S2.13), and within two distinct foci from an individual prostate tumor (Figure S2.14). Thus, 
SPOP mutation and ETS fusions may represent early and divergent driver events in prostate 
carcinogenesis. SPOP mutations were identified in LCM-analyzed high-grade intraepithelial neoplasia 
(HG-PIN) adjacent to invasive adenocarcinoma, further strengthening the premise that SPOP mutation 
comprises an early event in prostate tumorigenesis (Figure S2.15).  
In light of prior studies suggesting that prostate cancer may be classified by co-occurring genomic 
alterations (Demichelis et al., 2009; Lapointe et al., 2007; Taylor et al., 2010) we investigated whether 
SPOP-mutant tumors were enriched for other genomic lesions (Figure 2.4). Recurrent somatic deletions  
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Figure 2.4.  SPOP mutation defines a distinct genetic subclass of prostate cancer   
(A) Frequency of genomic copy number alterations in SPOP-mutant and SPOP-wildtype tumors. Length 
of bars reflects the frequency of copy number loss (blue) or gain (red).  
(B) Heatmap showing selected recurrent somatic copy number aberrations (SCNA). Each row represents 
a single prostate cancer sample. Samples are annotated for mutations in SPOP, PTEN, PIK3CA, and 
TP53, deletions of PTEN, and ERG rearrangements. Deletions positively correlated (5q21, 6q21) or 
inversely correlated (21q22.3) with SPOP mutation are shown. p-values of peak association with SPOP 
mutation in both discovery and validation cohorts are displayed at bottom (Fisher’s exact test). Regions 
are not to scale; full coordinates available in Table S2.8. 
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at 5q21 and 6q21 were enriched in SPOP-mutant tumors (p = 1.4x10 -11 and p = 3.4x10 -7, respectively, 
Fisher’s exact test) both in the whole-exome cohort and an independent prostate cancer collection 
(Figure 2.4, Table S2.8). Thus, loss of tumor-suppressor genes in these regions may collaborate with 
SPOP mutation to promote tumorigenesis. The relevant 5q21 locus contains CHD1, which encodes a 
chromatin-modifying enzyme that also undergoes disruptive rearrangements in prostate cancer (Berger et 
al., 2011). The 6q21 region encompasses several genes including FOXO3, a FOXA1 homologue that has 
previously been implicated in prostate carcinogenesis and progression (Shukla et al., 2009), and PRDM1, 
a tumor suppressor in lymphoma (Mandelbaum et al., 2010). In contrast, TP53 lesions were generally 
absent in SPOP-mutant tumors (p = 0.015, Fisher’s exact test), despite the fact that this tumor suppressor 
gene was recurrently mutated and deleted (Figure 2.1). SPOP mutations also trended inversely with point 
mutations and/or copy number loss involving the PTEN locus in primary tumors (p = 0.044, Fisher’s exact 
test) (Fig. 2.4); this pattern was supported by FISH analysis for PTEN deletion (Figure S2.16). SPOP-
mutant tumors also lacked PIK3CA mutations (Figure 2.4). Although the inverse relationship between 
SPOP mutations and PTEN/ PIK3CA alterations was evident in primary tumors (p = 0.041, Fisher’s exact 
test), these events co-occurred more frequently in metastatic tumors (Figure S2.16). Further studies are 
needed to determine if these genetic relationships also occur in other patient populations, and to 
elucidate the biological interactions that may underlie this phenomenon. Taken together, these results 
suggest that SPOP mutations may anchor a distinct genetic subtype of ETS-negative cancers. 
 
Conclusion 
 
In summary, whole-exome sequencing has identified genes that are recurrently mutated in 
prostate cancer. These efforts have also revealed a distinct ETS fusion-negative subclass of prostate 
cancer characterized by recurrent SPOP mutations and enriched for both 5q21 and 6q21 deletions. In the 
future, this expanded genetic framework may articulate new mechanisms of carcinogenesis that inform 
both disease modeling and patient stratification for clinical trials of experimental agents. Together with 
additional comprehensive analyses of the prostate cancer genome, epigenome, and transcriptome, these 
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systematic approaches should illuminate the landscape of alterations that underlie disease biology and 
therapeutic vulnerability in this common and clinically heterogeneous malignancy. 
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Methods 
 
Description of prostate tumor cohorts 
 
Clinically localized primary prostate cancers were selected for exome- and transcriptome-
sequencing from two cohorts: Weill Cornell Medical College (WCMC; New York, NY) and Uropath (Perth, 
Australia), a commercial supplier of banked urological tissues. Patients were included only if they had not 
received previous treatment for prostate cancer, including radiation therapy, brachytherapy or hormone 
ablation therapy. 
Tumors from the WCMC cohort were collected by the Institutional Biobank from patients 
undergoing radical prostatectomy by one surgeon for clinically localized prostate cancer. Patient-matched 
normal DNA was obtained from whole blood samples as described below for this cohort. 
Tumors from the Uropath cohort were obtained from men undergoing radical prostatectomy for 
clinically localized prostate cancer across multiple medical centers in Western Australia. Radical 
prostatectomies were performed by one of 30 clinicians between 2000 and 2010. Samples from both 
cohorts were stored at -80°C. Paired normal DNA was derived and sequenced from benign prostate 
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tissue. Normal DNA, was extracted from frozen tissue blocks with no histological evidence of neoplasia to 
minimize the possibility of contamination from tumor DNA. 
For both cohorts, Hematoxylin and Eosin (H&E)-stained tissue sections were centrally reviewed 
by Juan-Miguel Mosquera, Kyung Park and Mark Rubin to verify Gleason score and to determine the 
percentage of Gleason pattern 4 and 5 histology at the site selected for DNA extraction. To characterize 
the ethnic composition of the cohorts, we analyzed high-density SNP array data by principal component 
analysis in combination with data from cohorts of known ethnicity from the HapMap database (CEU, YRI, 
CHB/JPT; http://hapmap.ncbi.nlm.nih.gov/) (Figure S2.17). All but five individuals chosen for exome 
sequencing clustered with CEU HapMap samples, indicating that patients were predominantly Caucasian. 
Four samples showed mixed or undetermined ethnicity and one clustered clearly with CHB/JPT (Han 
Chinese in Beijing/Japanese in Tokyo) HapMap samples. 
In addition to exome- and transcriptome-sequenced tumors, prostate tumor cohorts from 
University of Michigan (UM), University of Washington (UW) and University Hospital Zurich (UZH) were 
used for extension screening for SPOP mutation. Prostate samples from the UM cohort were obtained 
from the radical prostatectomy series at the University of Michigan and from the Rapid Autopsy Program 
(Rubin et al., 2000), University of Michigan Prostate Cancer Specialized Program of Research Excellence 
Tissue Core (Ann Arbor, MI). Tumors from the UW cohort were obtained from the Rapid Autopsy 
Program, University of Washington and Fred Hutchison Cancer Research Center University (Seattle, 
WA). Samples from the UHZ cohort included a series of radical prostatectomy specimens, metastases, 
and benign prostatic hyperplasia samples. H&E–stained slides of all specimens were reevaluated by two 
experienced pathologists (Peter Wild and Colm Morrissey) to identify representative tissue sections. 
Tumor stage and Gleason score of the Zurich cohort were assigned according to the International Union 
Against Cancer and World Health Organization/International Society of Urological Pathology criteria. 
All samples were collected with informed consent of the patients and prior approval of the 
institutional review boards (IRB) of respective institutions. Additionally, the sequencing and data release 
of all exome- and transcriptome- sequenced samples was reviewed and approved by local IRB. 
 
DNA extraction for exome sequencing 
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H&E slides were cut from all frozen tissue blocks and examined by a board-certified pathologist to 
select for high-density cancer foci with <10% stroma or other noncancerous material to ensure high purity 
of cancer DNA. Biopsy cores were then taken from the corresponding frozen tissue block for DNA 
extraction. From each sample, 25-30mg of tissue was homogenized using a tissuelyser for 20 seconds at 
15Hz. DNA was then isolated from the homogenate using the QIAamp mini kit (Qiagen) following the 
manufacturer’s protocol. Samples were eluted in 150ul AE elution buffer and quantified using Picogreen 
dsDNA Quantitation Reagent (Invitrogen). Samples were qualified on an agarose gel (E-Gel, Invitrogen) 
to assess structural integrity. All DNA samples were stored at -20°C. 
 
Whole exome capture library construction 
 
Whole-exome hybrid capture libraries were constructed as described previously (Fisher et al., 
2011), with minor modifications. Concentrations of tumor and normal DNA were measured using 
PicoGreen dsDNA Quantitation Reagent (Invitrogen). We sheared 100ng of genomic DNA to a range of 
150-300bp using the Covaris E220 instrument. DNA fragments were end-repaired, phosphorylated, 
adenylated at the 3’ termini and ligated to Illumina sequencing adapters as describe (Fisher et al., 2011), 
except that standard paired end adapters were replaced with forked adapters containing unique 8 base-
pair index sequences (barcodes). Adapter-ligated DNA was then size-selected for lengths between 200-
350bp and subjected to exonic hybrid capture using SureSelect v2 Exome bait (Agilent) according to 
(Fisher et al., 2011). The targeted exome covered 44Mb and comprised 98.2% of the CCDS database as 
of November 2010. 
 
Library Quantitation and Sequencing 
 
The number of properly adapter-ligated fragments in each library was quantified using 
quantitative PCR (qPCR) (Kapa Biosystems) with specific probes for the ends of the adapters. Based on 
qPCR quantification, libraries were normalized to 2nM and then denatured using 0.1 N NaOH. Barcoded 
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whole-exome libraries were pooled at equal molarities prior to sequencing with up to 93 samples per pool. 
Cluster amplification of denatured templates was performed according to manufacturer’s protocol using 
V2 HiSeq Cluster Kits and V2 or V3 HiSeq Flowcells (Illumina). Paired end sequencing (2 x 76bp) was 
carried out on HiSeq Instruments, using V3 HiSeq Sequencing-by-Synthesis kits. The resulting data were 
analyzed with the current Illumina pipeline. Standard quality control metrics including error rates, % 
passing filter reads, and total Gb produced were used to characterize process performance prior to 
downstream analysis. The 8bp adapter index of each sequence read was used to match the read to its 
corresponding sample in the downstream data aggregation pipeline. 
 
Exome sequence data processing 
 
Two Broad Institute pipelines were used in succession to process and analyze exome 
sequencing data (Berger et al., 2011; Chapman et al., 2011; Stransky et al., 2011): 
 
(1) The sequencing data processing pipeline “Picard”, developed by the Sequencing Platform at the 
Broad Institute, starts with the reads and qualities produced by the Illumina software for all lanes and 
libraries and generates a BAM file (http://samtools.sourceforge.net/SAM1.pdf) representing each tumor 
and normal sample. The final BAM file stores all reads with well-calibrated qualities together with their 
alignments to the genome (only for reads that were successfully aligned). 
 
(2) The Broad Cancer Genome Analysis pipeline, also known as “Firehose”, starts with the BAM files for 
the tumor and matched normal samples and orchestrates various analyses, including quality control, local 
realignment, mutation calling, small insertion and deletion identification, coverage calculations and others 
(see details below). 
Several of the tools used in these pipelines were developed jointly by the Broad Institute 
Sequencing Platform, Medical and Population Genetics Program, and Cancer Program as part of the 
Genome Analysis Toolkit (GATK) (http://www.broadinsitute.org/gatk). Additional details regarding these 
pipelines are provided elsewhere (DePristo et al., 2011; McKenna et al., 2010). 
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Sequence data processing pipeline (Picard) 
 
For each sample, a BAM file was generated from Illumina sequence reads using the Picard 
pipeline (http://picard.sourceforge.net/) as previously described (Berger et al., 2011; Chapman et al., 
2011). Briefly, Picard executes four steps: (1) alignment of sequence reads to the genome; (2) 
recalibration of base qualities based upon the quality score given by the Illumina software, the read-cycle, 
the lane, the tile and the identity of the base and the preceding base; (3) aggregation of lane-level and 
library-level data into a single BAM file per sample; and (4) marking of artifactual duplicate read pairs. 
These steps were performed as in (Chapman et al., 2011), with the following modification: sequence 
reads were aligned to the NCBI Human Reference Genome GRCh37 using the Burrows-Wheeler Aligner 
(BWA) (http://bio- bwa.sourceforge.net) (Li and Durbin, 2009). 
The 224 BAM files produced by Picard, corresponding to 112 tumors and 112 normal samples, 
were deposited to dbGAP under accession no. phs000447.v1.p1. 
 
Cancer genome analysis pipeline (Firehose) 
 
We used Firehose, a cancer genome analysis pipeline infrastructure developed at the Broad 
institute, to analyze exome sequence data. The Firehose interface manages input files, output files and a 
variety of analysis tools. Firehose submits input files and parameters to GenePattern (Reich et al., 2006), 
which executes the specified modules or analyses. The analyses described below were performed as in 
(Berger et al., 2011; Chapman et al., 2011), with modifications where indicated. 
 
Quality control 
 
We used quality control modules in Firehose to ensure that each tumor and normal file 
corresponded to the correct individual, and that no mix-ups had occurred between tumor and normal data 
for a given individual. We compared genotypes from Affymetrix SNP 6.0 arrays and from tumor and 
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normal sequence data for each individual to ensure that all data corresponded to the correct patient. 
Genotypes from SNP arrays were also used to monitor for low levels of cross-contamination between 
samples from different individuals in sequencing data with the ContEst algorithm (Cibulskis et al., 2011). 
 
Identification of somatic single nucleotide variants (SSNVs) 
 
We used the MuTect algorithm from the Broad Institute Genome Analysis Toolkit (GATK) to 
identify SSNVs (https:// confluence.broadinstitute.org/display/CGATools/MuTect). As previously described 
(Berger et al., 2011; Stransky et al., 2011), MuTect identifies candidate SSNVs by performing a statistical 
analysis of the bases and their read qualities in the tumor and normal BAMs at the genomic locus under 
examination. Base-pairs were required to be covered by at least 14 reads in the tumor and 8 in the 
normal for mutation detection. 
 MuTect first filters out reads with low quality scores or excessive mismatches. A statistical 
analysis is then performed to identify somatic mutations using Bayesian classifiers for the tumor and 
normal sequences at a given locus: 
  
Thresholds were chosen for each statistic to achieve a sufficiently low false positive rate. Several post-
processing filters are applied to remove artifactual calls. For example, mutations are excluded that appear 
solely at the 5' or 3' end of reads or that are identified in panels of genomes from non-cancerous tissue. A 
subset of mutations was chosen for independent validation (see “Validation of selected mutations by 
mass spectrometry genotyping”). Mutations in known cancer-associated genes were reviewed manually 
using Integrative Genomics Viewer (IGV) (Robinson et al., 2011).  
 
Local realignment and detection of indels 
 
!"#!! = !"#!" ! observed!data!in!tumor! !site!is!mutated! observed!data!in!tumor! !site!is!reference  
 !"#! = !"#!" ! observed!data!in!normal! !site!is!reference! observed!data!in!normal! !site!is!mutated  
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To improve detection of small insertions and deletions (indels), reads in tumor and paired normal 
were jointly realigned at genomic locations harboring putative indels by the local realignment module in 
the GATK (DePristo et al., 2011). Putative indels were then considered at sites that were well covered in 
tumor and normal where the indel-containing allele was supported by 8 or more reads or 30% of all reads 
from the locus. Next, these indel calls were filtered based on local alignment statistics around the putative 
event, including the average number of additional mismatches per indel-supporting read, average 
mismatch rate and base quality in a small window around the indel (The Cancer Genome Atlas Network, 
2011).  
 
Determination of mutation rates 
 
We calculated rates of base mutations per Mb using the mutations detected (SSNVs and indels) 
and coverage statistics. Mutations were partitioned into categories based on their relative frequency such 
as (1) a C in a CpG dinucleotide mutated to T (CpG C to T transition), (2) all other Cs mutated to T (non-
CpG C to T transition), (3) mutation of any C to G or A and (4) mutation of A to any other base. Disruptive 
mutations such as frame-shift indels and nonsense mutations were also considered separately. 
Because mutations may accumulate in benign-appearing tissue, we determined whether the use of 
benign prostate as the source of normal DNA affected our ability to distinguish somatic alterations from 
germline events. Tumors with matched normal prostate (n = 89) did not show different rates of mutation 
from tumors with blood matched normal (n = 22) (Figure S2.4), suggesting that the use of normal prostate 
did not prevent the detection of tumor-specific mutations. 
 
Identification of significantly mutated genes 
 
We applied the MutSig algorithm from the Broad Institute to identify genes that were significantly 
enriched for mutations as previously described (Berger et al., 2011; Chapman et al., 2011)
 
with two 
modifications. First, at most one mutation per gene was considered from each sample. Second, the 
observed number of silent mutations was used as a guide to the local background mutation rate. Briefly, 
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MutSig identifies genes that harbor more mutations than expected by chance given sequence context and 
genic territory. Because certain base contexts exhibit increased mutation rates, such as cytosine in CpG 
dinucleotides, the context-specific mutation rates are considered for each class of mutation listed under 
“Determination of mutation rates” above. For each gene, we calculated the probability of detecting the 
observed constellation of mutations or a more extreme one, given the background mutation rates 
calculated across the dataset. This was done by convoluting a set of binomial distributions, as described 
previously (Getz et al., 2007). This p-value is then adjusted for multiple hypotheses according to the 
Benjamini-Hochberg procedure for controlling False Discovery Rate (FDR) (Benjamini, 1995) to obtain a 
q-value. The hyper-mutated sample (PR-00-1165) was excluded from this analysis.  
 
Identification of significantly mutated gene sets 
 
We also used MutSig to determine whether particular gene sets were enriched for mutations 
(Berger et al., 2011; Chapman et al., 2011). We downloaded the list of canonical pathways used in Gene 
Set Enrichment Analysis (GSEA) and analyzed 616 gene sets corresponding to known pathways or gene 
families. For each gene set, we tabulated the number of mutations occurring in any component gene, as 
well as the total number of covered bases in all genes in the gene set. A p-value was calculated for each 
gene set as for each gene, then a q–value was computed to account for the list of 616 hypotheses. The 
hyper-mutated sample (PR-00-1165) was excluded from this analysis. Indels called in significantly 
mutated genes and other cancer-associated genes were manually reviewed by inspecting the tumor and 
normal BAM files in IGV. 
 
Mutation annotation 
 
Point mutations and indels identified were annotated using Oncotator (Ramos et al, submitted) 
which integrates information from publicly available databases. In brief, a local database of annotations 
compiled from multiple public resources was used to map genomic variants to specific genes, transcripts, 
and other relevant features. The set of 73,671 reference transcripts used were derived from transcripts 
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from the UCSC Genome Browserʼs UCSC Genes track (Fujita et al., 2011) and microRNAs from 
miRBase release 15 (Kozomara and Griffiths-Jones, 2011) as provided in the TCGA General Annotation 
Files 1.0 library (https://wiki.nci.nih.gov/display/TCGA/RNASeq+Data+Format+Specification). Variants 
were also annotated with data from the following resources: dbSNP build 132 (Sherry et al., 2001), UCSC 
Genome Browserʼs ORegAnno track (Griffith et al., 2008), UniProt release 2011_03 (Uniprot Consortium, 
2011) and COSMIC v51 (Forbes et al., 2011). 
 
Validation of selected mutations by mass spectrometric genotyping 
 
In order to validate detected mutations with an orthogonal genotyping method, we chose 240 
non-silent mutations (231 SSNVs and 9 indels) across 48 T/N pairs to assay by mass spectrometric 
genotyping using the iPLEX platform (Sequenom). We targeted 74 mutations in significantly-mutated 
genes or gene sets with a q-value <0.1 and mutations reported in COSMIC. The remaining 166 non-silent 
mutations were chosen at random. Because the rate of validation using this technology falls significantly 
when the mutant allele is present at low allelic fraction (Berger et al., 2011; Stransky et al., 2011), we 
attempted to validate only mutations with AF ≥ 0.2 (i.e., where 20% of sequence reads from the tumor 
contain the mutation). 
Of the 240 assays attempted, 228 gave successful genotype calls and 218 somatic mutations 
were confirmed (listed in Table S2.3). All events called in the tumor were absent from the corresponding 
normal. We conclude that the overall accuracy for mutation calling was 95.6% (CI: 92%-98%; Clopper- 
Pearson 95% confidence interval), in close agreement with previous studies (Berger et al., 2011; 
Chapman et al., 2011). 
 
High-density SNP array analysis and detection of somatic copy number alteration 
 
Genomic DNA from tumor and paired blood samples was processed using Affymetrix Genome-
Wide Human SNP Array 6.0 (Affymetrix, Inc.) according to manufacturer’s protocols. The DNA was 
digested with NspI and StyI enzymes (New England Biolabs), ligated to the respective Affymetrix 
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adapters using T4 DNA ligase (New England Biolabs), amplified (Clontech), purified using magnetic 
beads (Agencourt), labeled, fragmented, and hybridized to the arrays. Following hybridization, the arrays 
were washed and stained with streptavidin- phycoerythrin (Invitrogen). Following array scanning, data 
preprocessing was performed using Affymetrix Power Tools. Copy number data was evaluated after 
segmenting the log2 ratios between tumor and paired normal levels on a sample basis. Quality control, 
data integrity, segmentation and copy number analysis were performed as previously described 
(Demichelis et al., 2009) with one additional step aimed at diminishing the number of recurrent lesions 
possibly caused by germline signal: we applied the same detection pipeline on the normal DNA samples 
alone. All peaks detected in both analyses were excluded from the recurrent somatic copy number 
aberration list. Cleared lesions with q-value < 0.1 were retained for association analysis with gene 
mutation status. Two-tail Fisher’s Exact Test was applied for all association tests. Copy number profile 
images were generated with IGV (Robinson et al., 2011). 
 
Assessment of tumor purity 
 
Because prostate tumors may contain significant amounts of admixed stroma, we determined 
whether the purity of cancer DNA limited our ability to detect mutations. We assessed tumor purity by 
considering the allelic fractions (AF) of mutations detected in each tumor, defined as the number of 
mutation- supporting reads divided by the total number of reads mapping to a mutated locus. AF can be 
influenced by several factors in addition to tumor purity, including copy number alterations at mutated 
sites and the presence of subclones within a tumor. Therefore, we used AF data to assess purity in two 
ways. First, we considered the maximum mutant AF across all mutations in each tumor after removing the 
top fifth percentile of AF values in order to exclude outliers with elevated AF due to copy number 
alterations or stochastic effects. Second, we considered the median AF for all mutations across a tumor.  
Both the maximum and median AF values correlated only slightly with the number of mutations 
detected, suggesting that tumor purity was not a systematic barrier to identifying mutations. In order to 
compare mutation rates across subgroups of tumors (e.g. Stage pT2 versus pT3), we verified that no 
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systematic differences in tumor purity existed between subgroups. To this end, we compared mutant and 
maximum AF for each subgroup and identified no differences (Figure S2.4). 
 
RNA extraction, RNA-Seq sample preparation and sequencing 
 
RNA was extracted from the frozen cancer tissue using TRIzol (Invitrogen) according to the 
manufacturer's protocol. Total RNA was prepared in accordance with Illumina's sample preparation 
protocol for paired end (PE) sequencing of mRNA as previously described (Pflueger et al., 2011). In brief, 
5–10 µg of total RNA was fragmented by heat between 2 and 3 min based on the desired insert size, 
reverse-transcribed using Superscript II (Invitrogen), and transformed to double-stranded cDNA. To 
improve PE RNA-Seq data quality, we introduced an additional gel-based size selection step after cDNA 
double-strand synthesis and before the ligation of the PE adapters. This was postulated by Quail et al. 
(Quail et al., 2008) as a means to reduce the inclusion of artifactual chimeric transcripts that are 
composed of two cDNA fragments into the sequencing library. We also integrated the use of T4 ligase 
(Enzymatics Inc.) to improve the efficiency of adapter ligation. Over the course of the study, we increased 
the library size range from 250 bp to 450 bp. The gel dissolutions of all gel-based purification steps were 
conducted at room temperature under slight agitation as described by Quail et al. (Quail et al., 2008). 
After the enrichment of cDNA template by PCR, the concentrations and the sizes of the libraries were 
measured using a Qubit fluorometer (Invitrogen) and DNA 1000 kit (Agilent Technologies) on an Agilent 
2100 Bioanalyzer, respectively. PE RNA- seq was performed with the Genome Analyzer II (Illumina) 
increasing the read size of the PE reads from 36 to 54 bp over the course of the study. Additionally, 
Illumina introduced improved sequencing reagents and upgraded imaging software over time to increase 
data quality and sequencing coverage. 
 
Processing of RNA-Seq data 
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PE reads were aligned to the human genome (hg18) using ELAND, part of the standard software 
suite from Illumina, as previously described (Pflueger et al., 2011). Data were visualized using IGV 
(Robinson et al., 2011), and candidate mutations were identified in SPOP coding regions. 
 
DNA extraction and SPOP genotyping 
 
DNA was extracted using phenol-chloroform and purified by ethanol precipitation method as 
previously described (Berger et al., 2011). Direct Sanger sequencing of putative SPOP somatic mutations 
in all tumor-blood pairs was performed by standard methods following PCR amplification using specific 
primers. Sequences of the primers used for amplifying and sequencing SPOP are given in Table S2.9. 
 
Laser-capture microdissection 
 
5µm-thick tissue sections were cut, fixed and stained on membrane coated slides followed by 
dissection with the ArcturusXTTM LCM Instrument (Life Technologies Corporation, California, USA). 
Tissue staining and Laser Capture Mircodissection (LCM) were performed by Mirjam Blattner and Kyung 
Park as described by Espina et al. (Espina et al., 2006). A combined IR capture and UV laser cutting was 
carried out to best recover a precise subset of cells. DNA was amplified as suggested by manufacturer 
with the Whole Genome Amplification kit (WGA4) for single cell approach (Sigma Aldrich). Standard PCR 
was used for targeted enrichment of SPOP exon 6 and 7 followed by Sanger sequencing. 
 
Fluorescence in situ hybridization 
 
The ETS rearrangement status and PTEN deletion status was assessed on tissue slides from the 
same tumor nodule used for RNA and DNA extraction.  Methods for fluorescence in situ hybridization 
(FISH) for TMPRSS2-ETS gene fusion have been previously described (Perner et al., 2006; Tomlins et 
al., 2005). We used ERG, ETV1, ETV4, and ETV5 break-apart FISH assays to confirm gene 
rearrangement on the DNA level (Svensson et al., 2011). To assess the status of PTEN, we used a locus 
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specific probe and a reference probe as previously described (Berger et al., 2011).  All FISH probes are 
listed in Table S2.10. 
 
Quantitative RT-PCR 
 
RNA was extracted using the TRIzol reagent (Invitrogen), subjected to DNase treatment (DNA-
free kit; Applied Biosystems) according to the manufacturer's instructions, and used in quantitative RT-
PCR. Quantitative RT-PCR was performed using the ABI 7500 Real-Time PCR System (Applied 
Biosystems) following the manufacturer's RNA-to-CT 1-step protocol. Each target was run in triplicate, 
and expression levels relative to the housekeeping gene GAPDH were determined on the basis of the 
comparative threshold cycle CT method (2−ΔΔCT). The primer sequences used in these experiments are 
given in Table S2.9.  All experiments were run in triplicate; results are representative of three independent 
experiments. 
 
Immunohistochemistry 
 
ERG rearrangement status was confirmed by immunohistochemistry as previously described 
(Park et al., 2010).  Briefly, primary rabbit monoclonal antibody was obtained from Epitomics. Antigen 
recovery was conducted using heat retrieval and CC1 standard, a high pH Tris/borate/EDTA buffer 
(VMSI). Slides were incubated with 1:100 of the ERG primary antibody for 1 hour at room temperature. 
Primary antibody was detected using the ChromoMap DAB detection kit and UltraMap anti-Rb HRP 
(VMSI). The anti-Rb HRP secondary antibody was applied for 16 minutes at room temperature. Slides 
were counterstained with Hematoxylin II for 8 minutes followed by Bluing Reagent (VMSI) for 4 minutes at 
37°C. Subjective evaluation of ERG protein expression was scored as positive or negative by study 
pathologists (Kyung Park, Juan-Miguel Mosquera and Mark Rubin) 
 
SPOP wild-type and mutant plasmids 
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Wild-type SPOP construct was obtained from Origene with C-terminal myc and FLAG tags in a 
mammalian expression vector. The SPOP-F133V construct was generated using the QuikChange II site-
directed mutagenesis kit (Agilent).  All plasmids were confirmed with Sanger sequencing, and protein 
expression was confirmed with Western blot using antibodies to SPOP, myc, and FLAG.  
 
Cell culture and transfection 
 
The human prostate cancer cell lines 22Rv1, and DU145 and the benign prostate epithelial cell 
line RWPE were obtained from the American Type Culture Collection.  22Rv1 and DU145Cells were 
maintained in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum (FBS) and 
penicillin/streptomycin.  RWPE cells were maintained in Keratinocyte-SFM (Invitrogen) supplemented 
with human recombinant Epidermal Growth Factor and Bovine Pituitary Extract (BPE).    
For siRNA transfection, RWPE (2.5 × 105 per well), 22Rv1 (4 × 105 per well), and DU145 (2 × 105 
per well), cells were seeded on 6-well tissue culture plates. The next day, cells were transfected with 100 
nM SPOP or nontargeting (control) siRNAs (ON-TARGETplus; Thermo Scientific) using Dharmfect 2 
reagent (Invitrogen) according to the manufacturer’s instructions. For plasmid transfection, DU145 (4 × 
105 per well), cells were seeded on 6-well tissue culture plates. The next day, cells were transfected with 
4 ug of pCMV6-WT SPOP or pCMV-SPOP-F133V using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions. 
 
Cell viability and proliferation assays 
 
22Rv1 (2 × 103 per well) and DU145 (1 × 103 per well) cells transfected with control or SPOP 
siRNA or SPOP plasmids were seeded in 96-well tissue culture plates. Cell viability and growth was 
determined by performing WST-1 assay (Roche) reading absorbance at 450 nm according to the 
manufacturer's instructions. Values from three wells were obtained for each treatment and timepoint. 
Results are representative of three independent experiments. 
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Invasion assays 
 
For invasion assays, 7.5 × 104 22Rv1 and 5 × 104 DU145 cells transfected with control or SPOP 
siRNA or SPOP plasmids were resuspended in 0.5 mL of RPMI-1640 medium containing 1% FBS and 
placed into the top chamber of Matrigel-coated 8-µm Transwell inserts (BD Falcon). The bottom wells 
contained RPMI supplemented with 5-10% FBS.  After 24h (DU145) or 48h (22Rv1), the filters were fixed 
and stained with Crystal Violet 0.5% for 30 min, and cells on the upper surface of the filters were removed 
with a cotton swab. Migrated cells were quantified by counting the numbers of cells that penetrated the 
membrane in four microscopic fields (at 20X objective magnification) per filter. All experiments were run in 
triplicate; results are representative of three independent experiments. 
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CHAPTER 3 
 
Complex DNA rearrangements result from punctuated 
genome-damaging events 
 
Adapted from: 
Baca, S.C., Prandi, D., Lawrence, M.S., Mosquera, J.M, Romanel, A., Drier, Y., Park, K., Kitabayashi, N., 
MacDonald, T.Y., Ghandi, M., et al. (2013). Punctuated evolution of prostate cancer genomes. Cell 153, 
666-77. 
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Introduction	  
  
Genetic studies of prostate cancer have revealed numerous recurrent DNA alterations that 
dysregulate genes involved in prostatic development, chromatin modification, cell cycle regulation and 
androgen signaling, among other processes (Baca and Garraway, 2012). Chromosomal deletions 
accumulate early in prostate carcinogenesis and commonly inactivate tumor suppressor genes (TSGs) 
such as PTEN, TP53 and CDKN1B (Shen and Abate-Shen, 2010). In addition, exome sequencing of 
localized and castration-resistant prostate cancer has identified base-pair mutations in genes such as 
SPOP, FOXA1 and KDM6A, which implicate a range of deregulated cellular processes in prostate tumor 
development (Barbieri et al., 2012; Grasso et al., 2012; Kumar et al., 2011). 
  Structural genomic rearrangements also play a critical role in prostate carcinogenesis. Roughly 
half of prostatic adenocarcinomas overexpress an oncogenic ETS transcription factor gene (most 
commonly ERG) due to somatic fusion with a constitutively active or androgen-regulated promoter 
(Tomlins et al., 2007; Tomlins et al., 2005). In addition, disruptive rearrangements may inactivate TSGs 
such as PTEN or MAGI2 (Berger et al., 2011). Interestingly, analysis of prostate cancer genomes has 
revealed complex “chains” of rearrangements, which may result when broken DNA ends are shuffled and 
re-ligated to one another in a novel configuration (Berger et al., 2011). In theory, these DNA-shuffling 
events could simultaneously dysregulate multiple cancer genes, but the prevalence and consequences of 
rearrangement chains could not be assessed with the small panel of tumors sequenced.  
 Given the importance of structural genomic alterations in prostate cancer genesis and 
progression, we performed whole genome sequencing (WGS) and DNA copy number profiling of 57 
prostate cancers to define a spectrum of oncogenic events that may operate during prostate tumor 
development. Through integrated analysis of rearrangements and copy number alterations, we 
discovered that the chromosomal disarray in a typical tumor may accumulate over a handful of discrete 
events during tumor development. We employ the term “chromoplexy” to describe this phenomenon of 
complex genome restructuring (from the Greek pleko, meaning to weave or to braid). Chromoplexy 
occurs in the majority of prostate cancers and may commonly inactivate multiple tumor-constraining 
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genes in concert, likely within a single clonogenic cell. This chapter describes the characterization of 
chromoplexy in prostate cancer genomes, and discusses how this knowledge informs a model for 
punctuated tumor evolution with relevance to prostate cancer and possibly other malignancies. 
 
The landscape of genomic rearrangement in prostate cancer 
 
We sequenced the genomes of 55 primary prostate adenocarcinomas and two neuroendocrine 
prostate cancer (NEPC) metastases that developed following castration-based therapy, along with paired 
normal tissue. We selected treatment-naïve adenocarcinomas across a range of clinically relevant tumor 
grades and stages (Gleason score 6 through 9; pathological stage pT2N0 through pT4N1; Table S3.1). 
Roughly 1.68x1013 sequenced base pairs aligned uniquely to the hg19 human reference genome (Table 
S3.2). Sequencing of tumor and normal DNA to mean coverage depths of 61x and 34x, respectively, 
revealed 356,136 somatic base-pair mutations, with an average of 33 non-silent exonic mutations per 
primary tumor (Figure 3.1 and Table S3.3A). We profiled somatic DNA copy number alterations (SCNAs) 
with high-density oligonucleotide arrays (Table S3.3B). Additionally, we conducted transcriptome 
sequencing on 20 tumors, along with matched benign prostate tissue for 16 cases.  
To identify genomic rearrangements, we analyzed paired-end sequencing reads that map to the 
reference genome in unexpected orientations using the dRanger algorithm (Berger et al., 2011). We 
observed 5596 high-confidence rearrangements that were absent from normal DNA in both this cohort 
and an extended panel of 172 non-cancerous genome sequences (Figure 3.1 and Table S3.3C). We 
validated 113 rearrangements by re-sequencing and/or PCR amplification of tumor and normal DNA 
(Table S3C). We did not discover novel recurrent gene fusions, but observed several singleton events 
that may lead to overexpression of oncogenes. For example, sense-preserving fusions joined NRF1 to 
BRAF (PR-4240) and CRKL to the ERK-2 kinase gene MAPK1 (P04-1084; Figure S3.1A), leaving the 
kinase domains of BRAF and MAPK1 primarily intact. Several genes underwent recurrent disruptive 
rearrangements with potential biological consequence, such as PTEN, RB1, GSK3B and FOXO1 (Figure  
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Figure 3.1. Somatic alterations in 57 prostate tumor genomes  
WGS was conducted on 55 prostate adenocarcinomas and two lung metastases from neuroendocrine 
prostate cancers (NEPC, *) along with paired normal DNA to detect somatic rearrangements and 
mutations. Gains and losses of DNA copy number at sites of recurrent SNCAs were detected with 
Affymetrix SNP 6.0 arrays (recurrent SCNAs were not assessed for sample P07-144, hatched lines). 
Bottom, cancer DNA purity was evaluated by assessing allelic ratios from sequence reads covering 
heterozygous single-nucleotide polymorphisms at sites of chromosomal deletion (see Methods). ETS 
gene fusions (ERG, ETV1) were detected by sequencing and validated by fluorescence in situ 
hybridization (FISH).   
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S3.1 and Table S3.4). Thus, rearrangement of these genes may contribute to development of localized 
prostate cancer. 
 
DNA deletions and rearrangements reveal signatures of complex genome-
restructuring events 
 
Rearrangements involving cancer gene loci often occurred in the context of a “chain”, in which the 
two rearrangement breakpoints map to the reference genome near breakpoints from other 
rearrangements (Figure 3.2A, left). Such characteristic breakpoint distributions were observed in our 
initial study of seven prostate cancer genomes (Berger et al., 2011) and appear to reflect collections of 
broken DNA ends that are shuffled and ligated to one another in an aberrant configuration. Given the 
involvement of prostate cancer genes in rearrangement chains, we set out to survey chained 
rearrangements systematically to clarify their prevalence, mechanistic underpinnings, and potential 
biological consequences. 
We first determined whether additional chains could be identified by integrative analysis of 
chromosomal deletions and rearrangements. Although rearrangement chains may arise with minimal loss 
of genetic material, substantial DNA deletions were often evident at the fusion junctions of chained 
rearrangements (Figure 3.2A, right). When these deletions are overlaid with somatic rearrangement 
locations on the reference genome, the deletions create “bridges” that span the sequence between 
breakpoints from two different fusions (Figure 3.2A, bottom right). In all informative tumors in our cohort, 
the breakpoints at either end of a deletion were more often fused to novel partners rather than to each 
other (thus creating “deletion bridges”, rather than “simple deletions”; Figure 3.S2A). Importantly, this 
observation indicates that the many rearrangements demonstrating DNA loss near a breakpoint may be 
linked by deletion bridges to additional rearrangements in a chain. 
We next considered whether rearrangements in a chain might arise independently of one 
another, for instance, at loci that are predisposed toward fusion due to DNA secondary structure or 
nuclear proximity (Burrow et al., 2010; De and Michor, 2011). To investigate this, we created a  
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Figure 3.2. Integrated analysis of genomic deletions and rearrangements reveals signatures of 
inter-dependent alterations 
(A) Three scenarios by which multiple DNA double-strand breaks may be repaired. Concerted repair with 
minimal loss of DNA (left) results in fusion breakpoints that map to adjacent positions in the reference 
genome. Loss of DNA at sites of double-strand breaks may result in simple deletions (middle) or “deletion 
bridges” (right) that span breakpoints from distinct fusions on the reference genome. Adjacent 
breakpoints or deletion bridges may provide evidence for chained rearrangements.  
(B) For the two breakpoints of each rearrangement (labeled A and B), the probability P of a second 
independently generated breakpoint (a or b) falling within the observed distance (L) was assessed based 
on the expected local rate of rearrangements (µlocal). The x- and y- coordinates represent the negative log 
of P for the two breakpoints in each fusion. Rearrangements near the upper right corner of the plot are 
unlikely to have arisen independently of other rearrangements. Observed rearrangements are compared 
to simulated and scrambled data. 
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probabilistic model for the independent generation of detectible rearrangements across the genome  
(Figure S3.2B). Using this model, we calculated the probability that any pair of neighboring DNA 
breakpoints X and Y would arise independently of each other (PXY) based on (1) their reference genome 
distance and (2) the local rate of rearrangements observed in our tumor panel (Figure 3.2B). As a control, 
we created ten simulated genomes for each tumor, with rearrangement locations matched for 
chromosome, local gene expression levels, sequence guanine/cytosine content and DNA replication 
timing, among other factors (see Methods). In addition, we generated “scrambled” genomes by drawing 
rearrangements from distinct tumors, preserving locus-specific effects that may promote double strand 
breakage. The observed rearrangements, but not the simulated or scrambled data, showed marked 
deviation from the independent model (Figure S3.2C) and statistical enhancement of chain-like patterns 
(Figure 3.2B). For 50% of rearrangements, the reference genome locations of both breakpoints were 
nearer to breakpoints of additional rearrangements than would be expected by chance (p < 10-4 for 
observed versus simulated or scrambled PXY values). To the extent that our model correctly predicts the 
genomic distribution of independent rearrangements, these results suggest that rearrangement chains 
are unlikely to arise from independent events, thus raising the hypothesis that they occur by a 
coordinated process.  
 
“Chromoplexy” generates chained chromosomal rearrangements and 
deletions 
 
Having identified chained patterns of adjacent rearrangements that may signify concerted 
alterations, we created an algorithm called ChainFinder to search for co-arising structural alterations 
(Figures 3.3A and S3.3). ChainFinder employs a statistically based search rooted in graph theory to 
identify genomic rearrangements and associated deletions that deviate significantly from our independent 
model described above, and thus appear to have arisen in an interdependent fashion (see Methods).  
We used ChainFinder to survey our panel of prostate tumors for rearrangement chains. Strikingly, 
this analysis revealed numerous chains involving widely variable numbers of rearrangements. Some  
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Figure 3.3 The ChainFinder algorithm 
(A) ChainFinder creates a graph representation of genomic breakpoints that may be linked in chains by 
somatic fusions, statistical adjacency or deletion bridges. ChainFinder assigns two neighboring 
breakpoints to the same chain if the p-value for their independent generation (P) is rejected with a false-
discovery rate below 10-2. For each cycle (closed path) within the graph, all scenarios are considered 
where one or more rearrangements in the cycle could have arisen independently. All rearrangements in a 
cycle are assigned to the same chain if every such scenario is rejected with a family-wise error rate below 
10-2 across all scenarios. Please see the Methods for additional details.   
(B) Circos plot of chained rearrangements in a prostate adenocarcima (P09-1042). Rearrangements 
depicted in the same color arose within the same chain; fusions in gray were not assigned to a chain. The 
inner ring depicts copy number gains and losses in blue and red, respectively.   
(C) The false positive rate of ChainFinder was assessed using simulated and scrambled genomes based 
on observed rearrangements. 
(D) For observed, simulated and scrambled genomes, the longest chain was compared along with the 
portion of breakpoints in any chain. 
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Figure 3.3 (continued) 
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chains involved only three fusions, while others revealed more than forty rearrangements that wove 
together five or more chromosomes (Table S3.5A; Figure 3.3B and S3.3C). We have termed the process 
of genomic restructuring that produces these complex chains “chromoplexy” (from the Greek pleko, 
meaning “to weave” or “to braid”). Chromoplexy-associated chains of five or more rearrangements (ten or 
more breakpoints) were detected in 50 out of 57 tumors (88%; Table S3.5B and Figure S3.3C), while 36 
tumors (63%) contained two or more such chains. Overall, 39% of rearrangements participated in chains, 
while ChainFinder detected chains in only 2.8% and 0.2% of rearrangements from simulated or 
scrambled genomes, respectively (Figure 3.3C-D). Thus, chromoplexy generates multiple structural 
alterations in a coordinated fashion, as inferred by statistical analysis of breakpoint distributions. 
We noted profound phenotypic differences in chromoplexy in subsets of prostate cancers. 
Chromoplexy in tumors harboring oncogenic ETS fusions (ETS+) produced significantly more inter-
chromosomal rearrangements than ETS- tumors (p < 10-4) and involved a greater maximum number of 
chromosomes in a single event (p = 9 x 10-3; Figure 3.4A-C). Interestingly, oncogenic ERG fusions 
frequently arose in the setting of chromoplexy (15 of 26 cases, 58%). Given that fusion of TMPRSS2 and 
ERG occurs in the setting of androgen receptor-driven transcription (Haffner et al., 2010), the intricate 
chains in ETS+ tumors could reflect DNA injury at transcriptional hubs occupied by loci from multiple 
chromosomes. Consistent with this possibility, chromoplexy in ETS+ nuclei primarily affected regions of 
the genome that are highly expressed in prostate tumors (Figure 3.4D) and that co-localize in interphase 
nuclei (Figure S3.4A). Thus, chromoplexy in ETS+ tumors appears to reflect a distinct process of genome 
restructuring that may be coupled to transcriptional processes.   
In contrast, chromoplexy in a subset of ETS-negative cancers resembled chromothripsis (Rausch 
et al., 2012; Stephens et al., 2011), a process of chromatin shattering yielding extensive DNA 
rearrangement, often of one or two focal chromosomal regions. In particular, seven ETS- tumors 
contained up to seven-fold more rearrangements than the whole-cohort average (Figure S3.4B). These 
tumors harbored focal deletions or disruptive rearrangements involving the chromatin-modifying enzyme 
gene CHD1, a putative tumor-suppressor gene that may regulate genomic stability (Huang et al., 2011; 
Liu et al., 2012). The rearrangements in CHD1del tumors were predominantly intra-chromosomal both 
within chains (p = 2 x 10-4) and overall (p = 4 x 10-4; Figure S3.4C). Moreover, the rearrangements in  
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Figure 3.4. Manifestations of chromoplexy vary by ETS fusion status 
(A) Circos plots of rearrangement chains in representative tumors, grouped by the presence of ETS 
rearrangements and CHD1 disruption. Rearrangements in the same chain are depicted in one color. 
Rearrangements in gray were not assigned to a chain. The inner ring shows copy number gain and loss 
in red and blue, respectively.  
(B) Rearrangement chains in ETS-positive tumors contain a greater proportion of inter-chromosomal 
fusions than chains in ETS-negative tumors.  
(C) The maximum number of chromosomes involved in a single rearrangement chain (y-axis), grouped by 
ETS status. The total number of breakpoints in chains in each tumor is depicted on the x-axis to allow 
comparison of tumors with similar degree of detectable chromoplexy.  
(D) ETS-positive chromoplexy breakpoints are enriched near DNA that is highly expressed in 16 prostate 
tumor transcriptomes.  
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Figure 3.4 (continued) 
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CHD1del samples arose in late replicating DNA with low guanine and cytosine content (Figure S3.4B), 
generally corresponding to gene-poor heterochromatin. An extended cohort of 199 prostate 
adenocarcinomas revealed that CHD1 loss was associated with an increased number of recurrent 
SCNAs (p = 1.5 x 10-8; Figure S3.4C). Given the postulated roles of CHD1 in genome stability and 
maintenance of chromatin architecture (Gaspar-Maia et al., 2009), these findings raise the possibility that 
CHD1 deletion may contribute to the distinctive patterns of genomic instability observed in CHD1del 
tumors. 
We investigated whether chromoplexy is unique to prostate cancer by analyzing a panel of 59 
additional tumor genomes including melanoma, non-small cell lung cancer, head and neck squamous cell 
carcinoma, and breast adenocarcinoma (Table S3.5B and Figure S3.3C). Every tumor type demonstrated 
multiple instances of chains involving 5 or more rearrangements. Thus, a small number of chromoplexy 
events may account for the wide array of rearrangements and deletions in several common cancers.   
 
Chromoplexy commonly dysregulates cancer genes 
 
 To assess the role of chromoplexy in prostate cancer development, we examined the genomic 
regions altered by deletion or disruptive rearrangements in the context of chains. Using a list of 17 
potential prostate tumor suppressor genes from the KEGG database (Kanehisa et al., 2012), we found 
that 26 of the 57 tumors (46%) have either deletion or rearrangement of at least one gene in a chain of 
three or more rearrangements (Table S3.5C). Inclusion of the TMPRSS2-ERG fusion and 10 putative 
prostate cancer genes added 9 more samples. Several cancer genes were recurrently deleted or 
rearranged by chromoplexy, including PTEN (9 cases), NKX3-1 (8 cases), CDKN1B (3 cases), TP53 (4 
cases), and RB1 (2 cases). Thus, chromoplexy may drive prostate carcinogenesis by disrupting tumor 
suppressor genes and creating oncogenic fusions. 
The concurrent shuffling and deletion of multiple regions across the genome that may underlie 
chromoplexy could simultaneously inactivate tumor suppressor genes that are geographically distant from 
each other (i.e. on separate chromosomes). We noted several examples where multiple putative cancer  
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Figure 3.5. Chromoplexy generates widespread genomic alterations that coordinately dysregulate 
multiple cancer genes  
(A) Chromoplexy-associated chain of 27 somatic rearrangements across 6 chromosomes in tumor P05-
3852, involving fusion of TMPRSS2 and ERG and disruptive rearrangement of SMAD4.  
(B) The putative tumor suppressor genes CDKN1B, ETV6 and ETV3 were lost in the context of deletion 
bridges in a 25-rearrangement chain affecting 3 chromosomes in PR-05-3595.  
In both panels, selected rearrangements were assessed by PCR of tumor and normal DNA.  
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genes were disrupted by a single instance of chromoplexy. For instance, a chain of 27 rearrangements 
across 6 chromosomes coordinately fused TMPRSS2 and ERG (21q) and disrupted the SMAD4 (18q) 
prostate tumor suppressor gene (Ding et al., 2011) (Figures 3.5A and S3.5). In a second example, the 
adjacent CDKN1B/ETV6 tumor suppressor genes (12p) and the ETV3 locus (1q) were lost in the context 
of deletion bridges within one chain (Figure 3.5B). Additional instances of chromoplexy disrupted 
interacting genes in the same pathway: for instance, deletion of PIK3R1 (5q) with PTEN (10q) and TP53 
(17p) with CHEK2 (22q) occurred in two chains (Table S3.5C). Thus, chromoplexy may simultaneously 
dysregulate multiple cancer genes across the genome. Such events may provide selective advantages to 
incipient cancer cells, particularly given that the loss of some TSGs promotes prostate cancer only in the 
context of specific accompanying molecular lesions (Chen et al., 2005).  
 
Clonal evolution reveals paths of prostate cancer progression 
 
To provide additional insight into the genomic evolution of prostate tumors, we analyzed the 
clonal status of mutations and deletions in our cohort. Using an approach related to previously described 
methods (Carter et al., 2012; Nik-Zainal et al., 2012), we exploited the extensive germline SNP genotype 
data provided by WGS to assess tumor purity and the clonal status of genomic lesions (Figures 3.6A and 
S3.6). Our estimates of tumor purity based on WGS matched those produced by ABSOLUTE analysis of 
SNP array data (Carter et al., 2012) (R2 = 0.99; p < 10-4), with the exception of two samples where 
admixed normal DNA was detected only from WGS data (Table S3.1).  
We first compared the clonality of deletions involving prostate cancer genes, reasoning that 
lesions that arise early in tumorigenesis or that foster rapid outgrowth would tend to be clonal, while late-
arising deletions would more often be subclonal. Several common deletions were strictly clonal, including 
NKX3-1 and the 3Mb region of chromosome 21q that is frequently deleted to produce the TMPRSS2-
ERG fusion (Perner et al., 2006) (Figure 3.6B and Figure S3.6). These events are among the earliest 
detectible alterations in prostate cancer and are frequently observed in prostatic intraepithelial neoplasia 
(PIN), a prostate cancer precursor lesion (Emmert-Buck et al., 1995; Perner et al., 2007). By contrast,  
 61	  
Figure 3.6. Clonality and evolution of prostate cancer  
(A) Schematic representation of the clonality assessment. The allelic fractions (AFs) of sequencing reads 
covering heterozygous SNPs were analyzed in order to assess the clonality of somatic DNA alterations. A 
hypothetical tumor is shown, composed of normal cells, a caner clone and a derivative subclone. The 
histograms indicate the expected SNP AFs within two deleted genes, A and B. The subclonal deletion of 
B yields a distinct distribution of AFs compared to the clonal deletion of A.  
(B) Selected deletions (top) and mutations (bottom) were classified as clonal or subclonal. Proportion test 
p-value is listed for the indicated comparisons. Independent samples (Barbieri et al., 2012) are included 
for support. 
(C) Example of clonal (TMPRSS2-ERG) and subclonal (CDKN1B) deletions from the same tumor. 
Histograms show the proportion of sequencing reads containing the reference allele for heterozygous 
SNPs in the deleted regions. A representative immunohistochemical stain for the CDKN1B protein p27Kip1 
shows discrete subclonal positivity in prostate cancer.  
(D) Patterns of tumor evolution were inferred based on clonality estimates. Arrows indicate the direction 
of clonal-subclonal hierarchy between genes that are deleted in the same sample in multiple cases. 
Deleted genes are represented by circles with size and color intensity reflecting the frequency of overall 
deletions and subclonal deletions, respectively. Ratios along the arrows indicate the number of samples 
demonstrating directionality of the hierarchy out of samples with deletion of both genes (ratios in 
parentheses refer to additional samples; Barbieri et al., 2012). The inset shows a similar analysis of point 
mutations (Barbieri et al., 2012).  
(E) The number of recurrent SCNAs and cancer DNA purity were compared across tumors with major 
Gleason pattern 4 versus 3.  
 
 
 
 
 62	  
 
Figure 3.6 (continued) 
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deletions of PTEN were often subclonal (p = 10-5 for comparison with NKX3-1 deletion clonality), as were 
CDKN1B deletions (Figure 3.6C). This finding suggests that PTEN and CDKN1B inactivation promotes 
the early progression of prostate cancer, consistent with the association of these events with higher-stage 
disease (Barbieri et al., 2012; Halvorsen et al., 2003).  
We next used our clonality assessments to deconvolve the sequence of oncogenic events that 
gives rise to a typical prostate tumor. Reasoning that clonal alterations must originate prior to subclonal 
alterations within the same tumor, we examined pairs of genes that were deleted in the same sample 
across multiple tumors to determine the directionality of the clonal-subclonal hierarchy (Figure 3.6D). 
Where possible, we confirmed these relationships in independent exome-sequenced tumors. A 
“consensus path” of progression emerged, beginning with events including deletion of NKX3-1 or FOXP1 
and fusion of TMPRSS2 and ERG. These lesions may disrupt normal prostate epithelial differentiation 
(Bhatia-Gaur et al., 1999; Sun et al., 2008) and effect other oncogenic perturbations. Thereafter, lesions 
in CDKN1B or TP53 accumulate; these alterations may lead to enhanced proliferation, genomic instability 
and/or evasion of apoptosis. Finally, loss of PTEN may provide a gating event in the development of 
aggressive prostate cancers. A similar assessment of point mutation clonality (Figure 3.6B, lower) 
revealed higher overall rates of subclonal events, with the exception of early mutations as in SPOP and 
FOXA1. Together, these results imply that prostate carcinogenesis favors the dysregulation of cancer 
genes in defined sequences, as has been suggested by studies of developing tumors in colon cancer 
(Fearon and Vogelstein, 1990).  
Next, we investigated whether chromoplexy might continue after cancer initiation, and thereby 
contribute to the progression of a tumor down an oncogenic path. Interestingly, several chains appeared 
to involve strictly subclonal deletion bridges (Figure S3.7A), indicating that tumors may sustain multiple 
rounds of chromoplexy. Together with the observation that chromoplexy targets both early and late genes 
in the consensus path (e.g., ERG and PTEN) these findings suggest that chromoplexy continues to drive 
the outgrowth of tumor subclones. 
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Prostate cancer genomic derangement increases with histological grade 
 
Finally, we considered whether tumors with high-grade histology (indicative of high clinical risk) 
might occupy positions further along the consensus path. To this end, we quantified recurrent SCNAs in 
each genome by counting amplifications and deletions that overlapped with regions of significant SNCAs 
identified by GISTICv2 analysis (e.g., the TP53, PTEN and CDKN1B loci) across 199 tumors reported 
here and in a previous study (Barbieri et al., 2012; Beroukhim et al., 2010). Tumors with predominantly 
Gleason score (GS) 4 histology were significantly enriched for recurrent SCNAs compared to GS 3 
tumors (p = 5.9 x 10-3; Figure 3.6E) beyond the overall extent of SCNAs, despite similar purity of cancer 
DNA and mutational burden between the two groups. Altogether, these findings suggest that structural 
alterations affecting cancer genes, many of which result from chromoplexy, may contribute to the 
aggressive clinical behavior of high-grade prostate tumors.  
 
Discussion 
 
 We have characterized somatic alterations across the genomes of 57 prostate tumors. By 
systematically profiling rearrangements and copy number alterations, we identified chromoplexy as a 
common process by which multiple geographically-distant genomic regions may be disrupted at once. 
Chromoplexy is evident in several solid tumor types and in the majority of prostate cancers. In multiple 
instances, chromoplexy altered more than one cancer gene coordinately. In the future, systematic 
assessment of chromoplexy from WGS data could reveal groups of cancer gene alterations that confer a 
selective advantage when sustained all at once, but activate tumor-suppressing safeguards if sustained 
individually.  
Although chained rearrangements could theoretically arise over multiple cellular generations by a 
“sequential-dependent” mechanism, where the occurrence of each subsequent event depends on the 
presence of a prior event (Figure S3.7B), such a mechanism seems unlikely. In particular, a sequential-
dependent model fails to account for the many complete or “closed” chains we detected. For a closed 
 65	  
chain to arise in a sequential-dependent manner, multiple junctions from ancestral somatic fusions would 
have to be re-broken precisely and fused to each other (Figure S3.7B) to complete the chain. Even if 
breakpoints in a chain could only fuse to one another, to generate the 121 observed closed chains in a 
sequential-dependent process would require immensely elevated rates of rearrangement in a focused 
region of the genome (up to ~103 times the maximum observed rate; Figure S3.7C-D). While we cannot 
exclude this possibility, plausible biological mechanism(s) could parsimoniously account for chained 
rearrangements within a single cell cycle. The interpretation that chromoplexy coordinately generates 
chained rearrangements awaits experimental validation, which could involve FISH or chromosome 
conformation capture (3C) before and after inducing a predicted co-localizing event (e.g., testosterone 
exposure in prostate epithelial cells). 
 A unifying feature of chromoplexy-associated alterations is that they occur in a non-independent 
fashion; however multiple mechanisms may account for chromoplexy. Along these lines, our analyses 
have revealed distinctive patterns of chromoplexy in ETS-, CHD1del tumors. Tumors with deletion of CHD1 
demonstrated an excess of intrachromosomal chained rearrangements and gene deletions, with DNA 
breakpoints enriched in GC-poor, late-replicating and non-expressed DNA. These tumors showed 
abundant, clustered rearrangements often affecting only one or two chromosomes with two alternating 
copy number states, perhaps indicating a chromothripsis-like process.  
 In contrast, chromoplexy in ETS+ tumors differed in the aggregate from chromothripsis in several 
critical ways. For example, single events joined DNA from dispersed regions of six or more chromosomes 
in multiple tumors, whereas chromothripsis frequently involves focal rearrangement of one or two 
chromosomes (Forment et al., 2012). Overall, chromoplexy appears more prevalent in ETS+ prostate 
cancer than chromothripsis is in any neoplasm (Forment et al., 2012; Stephens et al., 2011). 
Chromoplexy frequently involves fewer rearrangements than the “catastrophic” chromothripsis defined by 
Stephens et al., but may continue throughout tumor development. Our analysis of breakpoint locations in 
ETS+ tumors suggests that chromoplexy in this setting may be linked to proposed transcriptional DNA-
damaging processes (Lin et al., 2009), potentially related to androgen receptor signaling. Our findings 
align with the observation that ERG-overexpressing cancer cells accumulate DNA damage and are 
sensitive to poly ADP-ribose polymerase inhibition (Brenner et al., 2011). Chromoplexy is often active 
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prior to ETS gene fusions, however, and gave rise to ERG fusions in many instances. Ongoing analyses 
of cancer genomes may further elucidate mechanisms of chromoplexy and determine whether CHD1 loss 
might also denote PARP-dependency, given the high degree of intrachromosomal rearrangement in this 
context. 
Whole genome analysis also clarified the chronology of oncogenic events in prostate cancer 
progression, driven in part by chromoplexy. Genome-wide sequence coverage of germline SNPs allowed 
us to identify DNA lesions that arose after the founder clone was established. Subsequently, we 
demonstrated a progression of events within primary tumors that expands upon array-based SCNA co-
occurrence studies (Demichelis et al., 2009). A consensus path of tumor evolution begins with events 
such as loss of NKX3-1 or fusion of TMPRSS2 and ERG. The path proceeds with the loss of CDKN1B, 
TP53, and PTEN, among other progression-associated lesions. We found that the histological grade of 
cancer may partially reflect its progression down this path.  
 
A continuum model for tumor evolution 
 
Tumorigenesis is classically understood to progress by a gradual accumulation of oncogenic 
alterations in the genome of a pre-cancerous cell. This textbook view was recently challenged by the 
discovery of chromothripsis, in which catastrophic rearrangements are incurred by “shattering” and 
reassembly of focal regions of the genome (Forment et al., 2012; Rausch et al., 2012; Stephens et al., 
2011). 
We propose an expanded model for the evolution of prostate cancer, which may also apply to 
other cancers (Figure 3.7). As classically understood, passenger and driver alterations can accumulate in 
a cancer genome gradually over numerous cell divisions, via point mutations, simple translocations and 
focal copy-number alterations. On the opposite end of the spectrum, extreme instances of chromothripsis 
can induce massive (albeit relatively localized) DNA damage at once, often with oncogenic consequences 
(Rausch et al., 2012; Stephens et al., 2011). Between these two extremes lies a broad continuum across 
which chromoplexy may often restructure cancer genomes. We propose that oncogenic events along this 
continuum reflect “punctuated” tumor evolution, drawing an analogy from the observation that  
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Figure 3.7. A continuum model for the genomic evolution of prostate cancer  
Oncogenic aberrations may accumulate in cancer genomes gradually (left), by punctuated progression 
(middle) or in a single catastrophic event (right). Chromoplexy-associated rearrangements and deletions 
induce a modest to large degree of genomic derangement over several successive events. As indicated 
at bottom, larger-scale rearrangements that affect broader swaths of the genome may be more difficult for 
a cell to survive, and may tend to require co-occurring oncogenic lesions to become fixed in a tumor.  
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punctuated evolution of species may occur rapidly between periods of relative mutational equilibrium 
(Gould, 1977). By analogy, a tumor genome may sustain considerable damage over several sequential 
and punctuated events. Importantly, this framework accords with the observation that chromoplexy events 
(1) are common, (2) may involve a wide-ranging number of rearrangements, and (3) may continue after 
cancer-initiating lesions such as NKX3-1 deletion (Figure S3.7).  
A cancer might operate at any point along the continuum of progression at a given time. Tumors 
that develop primarily at the “catastrophic” end may require fewer events and could progress more 
quickly, because each such event could disrupt multiple cancer-constraining processes. At the same 
time, catastrophic events that cover diffuse genomic territory are more liable to disrupt essential or 
beneficial genes, thus imparting a selective disadvantage to (pre)malignant clones that sustain such 
events. Consequently, the model predicts that survivable chromoplexy (particularly near the catastrophic 
regime) is likely to involve oncogenic alterations that compensate for the incidental inactivation of 
essential genes (Figure 3.7). This prediction accords with the observation that most tumors show 
disruption of one or more putative prostate cancer genes within a chain. Moreover, this model raises the 
possibility that disruption of putative cancer genes by chromoplexy may heighten the probability that such 
genes represent “driver” events for that particular tumor. If so, this framework may hold important 
implications for the use of whole-genome sequencing in diagnostic and clinical studies. 
In summary, this study highlights the potential for WGS data to capture aspects of the “molecular 
archeology” of cancer development that are missed by gene- or exome-level sequencing. The 
characterization of clonal progression and chromoplexy in emerging large panels of cancer genomes may 
provide insights about cancer initiation and progression, with implications for cancer detection, prevention 
and therapy. 
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the breakpoint enrichment analyses. 
 
Methods 
 
Description of the tumor cohort 
 
Prostate cancers analyzed in this study originated from two of the cohorts described in Chapter 3 
(Barbieri et al., 2012) (Weill Cornell Medical College (WCMC; New York, NY) and Uropath Pty Ltd. (Perth, 
Australia), a provider of banked urological tissues). All prostate cancer samples were collected under an 
Institutional Review Board-approved protocol with the informed consent of patient donors. Sixteen tumors 
were characterized by exome-sequencing in a previous study (Table S3.1) (Barbieri et al., 2012). 
Previous analyses of SNP data from these cohorts indicated that patients were primarily of Caucasian 
ancestry (Barbieri et al., 2012). Primary adenocarcinomas were removed prior to any additional treatment 
for prostate cancer, including radiation therapy, brachytherapy or hormone ablation therapy. The two 
NEPC samples were reviewed by the study pathologists and confirmed as neuroendocrine carcinomas of 
prostatic origin based on clinical history and/or presence of ERG fusion (PR-7520). Immuno-
histochemistry was negative for PSA and positive for the neuroendocrine marker synaptophysin in both 
cases. 
 
Chromosomal copy number profiling 
 
Segmented copy number profiles were generated from Affymetrix SNP 6.0 human microarray 
data as described in Chapter 3 (Barbieri et al., 2012). Sites of significant recurrent copy number 
alterations were identified by GISTICv2 (Beroukhim et al., 2010), with a log2 threshold of +/- 0.1 for 
amplification/deletion signals.  
 
Sequencing data generation 
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WGS library construction 
 
Libraries were prepared as described previously (Fisher et al., 2011) with slight modifications. 
First, the genomic DNA input into shearing was reduced from 3µg to 100ng in 50µL of solution. In 
addition, for adapter ligation, Illumina paired-end adapters were replaced with palindromic forked 
adapters with unique 8 base index sequences embedded within the adapter. Size selection was then 
performed using Sage Bioscience’s Pippin Prep, with a target insert size of either 340bp or 370bp +/- 
10%.  
Following sample preparation, libraries were quantified using quantitative PCR (KAPA 
Biosystems) with probes specific to the ends of the adapters. This assay was automated using Agilent’s 
Bravo liquid handling platform. Based on qPCR quantification, libraries were normalized to 2nM and then 
denatured with 0.1 N NaOH using Perkin-Elmer’s MiniJanus liquid handling platform.  
 
RNA-Seq library construction 
 
RNA was isolated using a Dynabeads® mRNA Purifcation Kit (Life Technologies). Two rounds of 
poly-A selection (with bead regeneration) were performed to achieve rRNA contamination of less than 
10%, as assessed by the Bioanalyzer mRNA Pico program (Agilent). Eluate was treated with DNase 
(TURBO DNA-free™ kit, Ambion) at 37°C for 30 minutes then immediately cleaned using RNAClean XP 
beads (Agencourt). RNA was fragmented in Fragmentation Buffer (Affymetrix) at 80˚C for 4 minutes. 
First- and second-strand cDNA synthesis were performed with SuperScript Double-Stranded cDNA 
Synthesis Kit (Life Technology). Library construction proceeded as described previously (Fisher et al., 
2011), except that SPRI beads were used in the end-repair cleanup and standard paired-end adapters 
were replaced with barcoded adapters each containing a unique 8-base index sequence. After adapter 
ligation, two sequential cleanups were performed to remove adapter dimers, followed by 8 cycles of 
cDNA PCR amplification and SPRI cleanup. Before sequencing, samples were pooled and normalized 
according to qPCR results.      
 71	  
 
Cluster amplification and sequencing 
 
Cluster amplification of denatured templates was performed according to the manufacturer’s 
protocol (Illumina) using HiSeq v3 cluster chemistry and flowcells. Flowcells were sequenced with 101-bp 
paired end reads on a HiSeq 2000 using HiSeq v3 Sequencing-by-Synthesis Kits and analyzed using 
RTA v.1.12.4.2.  
 
Genome sequence analysis 
 
Sequencing data management and processing 
 
A BAM file was generated for each sample from Illumina sequence reads using the Picard 
pipeline (http://picard.sourceforge.net/). Reads were mapped to the NCBI Human Reference Genome 
GRCh37 (hg19) with the Burrows-Wheeler Aligner (BWA) (http://bio-bwa.sourceforge.net). (BAM files 
from WGS data, as well as RNA-Seq and SNP array data were deposited in the database of Genotypes 
and Phenotypes (dbGaP; phs000447.v1.p1)) 
The cancer genome analysis pipeline known as Firehose (Principal author D. Voet) was used to 
manage and coordinate analysis of WGS data. Firehose submits input files and parameters to 
GenePattern (DePristo et al., 2011), which executes a series of analyses to verify data quality and detect 
somatic alterations by comparing tumor and normal sequences.  
 
Quality control 
 
 We employed several quality control modules to monitor for contamination or potential sample 
mix-ups. To ensure that tumor- and normal-DNA were properly matched for a given individual and free of 
contaminating human sequences, we generated SNP fingerprints from 24 highly polymorphic sites for 
each sequencing lane. Lanes with outlier fingerprint genotypes for a given individual were discarded. In 
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addition, we used the ContEst algorithm (Cibulskis et al., 2011) to analyze homozygous non-reference 
SNPs to estimate levels of contamination with foreign human DNA, and required that samples 
demonstrate >95% concordance. 
 Normal DNA sequences were assessed for admixture with cancer DNA by examining copy 
number profile estimates based on sequence coverage in 100kb bins across the genome. Three normal 
tissue samples (PR-07-3258, PR-09-3983 and P05-2709) demonstrated low-level contamination with 
tumor DNA, based on similar patterns of DNA gains and losses between tumor and normal in a pair. In 
these cases, the histologically benign prostate tissue used as a source of normal DNA likely contained 
neoplastic or pre-neoplastic cells. The detection of somatic alterations in these samples was therefore 
limited. We specifically analyzed discarded rearrangement calls from these samples for prostate cancer-
associated fusions, and identified cases in which the TMPRSS2-ERG fusion was filtered out due to its 
presence in normal (see below).  
 
Detection of chromosomal rearrangements 
 
Detection of somatic rearrangements was performed using the dRanger algorithm (Berger et al., 
2011) to identify sequence reads from paired ends that map to the reference genome with unexpected 
orientations or intervals between read pairs. Candidate rearrangements were identified from clusters of 
such reads. They were then assigned a score by multiplying the number of chimeric reads supporting the 
fusion by a quality multiplier between 0 and 1. The quality multiplier takes into account the following 
factors: (1) the fraction of nearby reads with a mapping quality of zero; (2) the number and diversity of 
other discordant pairs in the vicinity of the breakpoints; and (3) the standard deviation of the starting 
positions of the supporting read pairs. Rearrangements with score of 4 or greater that were absent from 
the corresponding normal and from an extended panel of 176 non-cancerous genome sequences were 
classified as high-confidence. Rearrangements were categorized as deletions, inversions, 
interchromosomal translocations or tandem duplications based on the locations and strand directions of 
reads at fusion breakpoints.  
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In three cases, the TMPRSS2-ERG fusion was detected but filtered out, either due to low levels 
of tumor contamination in the adjacent prostate tissue used as a normal comparator (PR-09-3983, P05-
2709), or to an abundance of breakpoints at the locus that resulted in a low quality multiplier (PR-
STID0000000415). The TMRPSS2-ERG fusion was confirmed by fluorescence in situ hybridization 
(FISH) in these and all other fusion-positive cases.  
Some loci that were rearranged in the context of a chain harbored many breakpoints that 
decreased the rearrangement quality score and caused the rearrangement to be rejected, despite support 
from multiple tumor reads and the absence of the rearrangement in normal DNA. To improve our ability to 
detect chains in these situations, we adjusted the parameters of dRanger so that rearrangements were 
considered if they demonstrate five supporting reads in tumor DNA, no reads in the panel of normal 
genomes and a score of 1 or greater. Rearrangements falling into this category were retained in the final 
dataset only if they were assigned to a chain.  
 Breakpoint fusion junctions were mapped to base-pair resolution where possible using the 
BreakPointer algorithm (Drier et al., 2012). BreakPointer searches for read pairs where one read maps 
near a breakpoint and the pair mate partially overlaps with the fusion junction, or fails to align anywhere. 
These unmapped reads are subjected to a modified Smith-Waterman alignment procedure with the ability 
to jump between the two reference sequences at the most fitting point. BreakPointer mapped the 
breakpoints to base pair resolution in 94% of the 5596 high-confidence rearrangements. In these cases, 
sequence homology at fusion junctions and any foreign sequence insertions were annotated. 
Rearrangements were annotated with transcript information from the UCSC Genome Browserʼs 
UCSC Genes track (Table S3.3C) (Fujita et al., 2011) and illustrated using Circos 
(http://mkweb.bcgsc.ca/circos)  
 
Identification and annotation of point mutations 
 
  We used the MuTect and IndelLocator algorithms to identify point mutations and small 
insertions/deletions (indels), respectively, as described in Chapter 3 (Barbieri et al., 2012).  Point 
mutations and indels were annotated with information about relevant genes, transcripts, proteins and 
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other features using publicly available databases. A set of reference transcripts was compiled for 
annotation from the UCSC Genome Browserʼs UCSC Genes track as provided in the TCGA General 
Annotation Files (GAF) hg19 June 2011 bundle (https://tcga-data.nci.nih.gov/docs/GAF/). Variants were 
also annotated using the following resources: dbSNP build 134 (Sherry et al., 2001), UCSC Genome 
Browserʼs ORegAnno track (Griffith et al., 2008), UniProt release 2011_09 (Consortium, 2011) and 
COSMIC v55 (Forbes et al., 2011).  
 
Validation of somatic mutations and rearrangements 
 
Mutation validation from transcriptome sequences 
 
We assessed 818 somatic point mutations covering annotated transcripts in RNA-Seq data from 
20 tumors profiled by transcriptome sequencing (Table S3.3A). Of the mutated sites, 92 were covered by 
40 or more RNA-seq reads and present in WGS reads at an allele fraction of 0.2 or greater. Of these 
mutations, 84 (91%) showed at least two reads supporting the alternate allele.  
 
Validation of somatic rearrangements 
 
Rearrangements were validated by two approaches. We assessed a set of 73 rearrangements, 
enriched for events affecting cancer genes, by PCR and deep sequencing on a MiSeq instrument (Table 
S3.3C). Reads from tumor and normal DNA were aligned to a custom genome that contained the hg19 
reference genome along with sequences of all predicted somatic fusion junctions across samples. 
Rearrangements were classified as somatic if tumor, but not normal alignments, showed multiple high-
quaity reads spanning the predicted fusion junction.  
 In addition, we selected 76 chromoplexy-associated rearrangements for validation by PCR alone 
(Figure S3.5, Table S3.3C). Primers were designed to amplify approximately 200bp containing the 
predicted fusion junction. Rearrangements were annotated as somatic if a band of the predicted size was 
amplified from tumor DNA but not from normal DNA. 
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Fluorescence in situ hybridization validation of rearrangements 
 
ETS rearrangement was assessed using break-apart assays for ERG and ETV1 as described 
previously (Berger et al., 2011). To assess genomic deletion, gene fusion and disruptive translocations, 
we used locus-specific dual-color FISH assays following a previously described approach (Berger et al., 
2011; Perner et al., 2006). At least 50 nuclei were evaluated per tissue section using a fluorescence 
microscope (Olympus BX51; Olympus Optical). The following probes were used for FISH assays: 
 
Locus    BAC #  
CHD1    RP11-58M12 
CHD1 Reference (5p13.1) RP11-429D13 
  
GSK3B 3'   RP11-59M4 
GSK3B 5'   RP11-113H22 
  
JAK1 3'    RP11-1061K17 
JAK1 5'    RP11-76O023 
  
JAK2 3'    RP11-274A3 
JAK2 5'    RP11-259N10 
  
CRKL 3'   RP11-76I4 
CRKL 5'   RP11-1152E2 
  
MAPK1 3'   RP11-317J15 
MAPK1 5'   RP11-179H3 
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PTEN    CTD-2047N14 
PTEN Reference (10q25) RP11-431P18 
  
FOXP1    RP11-410B2 
FOXP1 Reference (3p11) RP11-91M15 
  
BRAF 3'   RP11-248P7 
BRAF 5'   RP11-248O23 
 
Protein-protein interaction (PPI) analysis of somatically rearranged genes  
 
 To identify gene rearrangements of potential biological consequence in Figure S3.1, we searched 
for recurrently rearranged genes whose protein products occupy central positions in interaction networks. 
To assess protein-protein interaction (PPI) network centrality, we considered the product of two measures 
of degree centrality and betweenness centrality:  
 
1. Degree centrality: Given a protein p and a PPI network N, the index Degree(p,N) measures the 
number of interactions incident upon p. The index is normalized by dividing D(p,N) with the 
maximum index in the network. 
 
2. Betweenness centrality: Given a protein p and a PPI network N, the index Betweenness(p,N) 
measures the number of shortest paths from all proteins to all others that pass through protein p. 
The index is normalized by dividing Betweenness(p,N) with the maximum index in the network. 
 
 We assessed centrality with the STRING database (Szklarczyk et al., 2011), and considered two 
other databases for independent support (Human Protein Reference Database (HPRD) (Prasad et al., 
2009) and I2D (Brown and Jurisica, 2007)). The top quartile of centrality indexes in the entire network of 
18,583 proteins was significantly enriched with protein products of the 397 genes with rearrangements in 
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more than one sample (p = 2 x 10-3). 
 For rearranged genes that scored highly in the centrality analysis, we assessed gene expression 
levels in the subset of transcriptome-sequenced samples using RSEQtools (Habegger et al., 2011) (Table 
S3.4). To evaluate the effects of the rearrangements on gene transcription, we noted genes that were 
expressed in the bottom or top tenth percentiles in samples harboring rearrangement of the locus 
compared to all other tumors. 
 
Detection of chained rearrangements and deletions 
 
Overview of the ChainFinder algorithm 
 
ChainFinder analyzes somatic DNA rearrangements from WGS data (e.g., deletions, inversions 
or translocations) and infers whether the rearrangement likely occurred in the context of a “chain” with two 
or more other rearrangements. Chained rearrangements are identified by searching for sets of 
breakpoints that are distributed about the genome in a configuration that would be improbable if the 
rearrangements had occurred independently of one another. The ability to detect chains is enhanced by 
also considering copy number profiles for signatures of chained rearrangements. 
ChainFinder is implemented in MATLAB, and formulates the detection of rearrangement chains 
as a graph theory problem, in which breakpoints are treated as nodes that may be inter-connected by 
graph edges (Figures 3.3A and S3.3A). Edges connect pairs of breakpoints that are either (1) somatically 
fused to each other (2) involved in two distinct rearrangements that are unlikely to have arisen 
independently or (3) at either end of a deletion bridge. An initial graph is constructed by searching for sets 
of breakpoints and associated deletions for which the independent model can be rejected after correction 
for multiple hypothesis testing (see below). The initial graph is then refined by considering any alternative 
valid assignments of breakpoints and deletion segments to deletion bridges. In the final graph, 
breakpoints connected by edges correspond to collections of rearrangements that may have arisen 
concertedly in the context of a chain.  
These steps are described in detail in the following sections and diagramed in Figure S3.3A. 
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Assessment of adjacent breakpoints 
 
Each pair of breakpoints joined by a somatic DNA fusion is first connected by an edge on the 
graph (Figure S3.3A). For each pair of neighboring breakpoints on the reference genome within 1Mb of 
each other, the probability of two breakpoints arising independently within the observed distance of one 
another (PXY) is calculated as follows. We assume that the probability of a DNA breakage event per 
nucleotide is uniform near the breakpoint and equal to µlocal. The probability of a second event not 
occurring within a distance L from the reference event (either upstream or downstream) is (1-
2µlocal)L. Therefore, the probability PXY of observing a second breakpoint Y within distance L of an index 
breakpoint X is: 
 
 PXY = 1- (1 - 2µlocal)L 
 
The rate µlocal is calculated based on (1) the number of breakpoints per base-pair observed in a given 
tumor (µglobal) and (2) the density of breaks near the rearranged locus across the panel of 57 prostate 
tumors (ρ): 
 
µlocal = µglobal ρ 
 
We estimate the breakpoint density ρ as a function of genomic location by dividing the genome into 1Mb 
windows and counting the number of tumors with one or more breaks within a given window (Figure 
S3.2B). Values of ρ are scaled uniformly such that the sum of µlocal across all windows is equal to µglobal. 
For neighboring breakpoint pairs, PXY is considered as a p-value for the hypothesis that the two 
breakpoints arose independently. Pairs of breakpoints are connected by an edge (assigned to the same 
chain) if the corresponding PXY can be rejected with control of the false discovery rate at 10-2 (Benjamini, 
1995). 
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Assignment of deletion bridges 
 
Next, segmented copy number data are overlaid with breakpoint locations to identify 
rearrangement breakpoints that correspond to deletion events. This step connects breakpoints on the 
graph with edges corresponding to deletion bridges in cases where the breakpoints may have originated 
from the same DNA deletion event.  
Each breakpoint is provisionally paired to a boundary of a deletion segment if the breakpoint lies 
within 8 SNP probes of the boundary (typically a span of several thousand base-pairs). Breakpoints at 
either boundary of a deletion segment are potentially joined by a deletion bridge if:  
 
A. The breakpoints on either end of the deletion are not fused to each other; i.e., the deletion must 
correspond to a deletion bridge (involving two rearrangements) rather than a “simple deletion” 
(involving one rearrangement) (Figure 3.2A). 
B. The sequencing reads supporting the breakpoints at either end of the deleted segment must 
“point towards” the deletion, such that the deleted sequence would lie directly downstream of the 
reads.  
 
Edges are added to the graph to denote potential deletion bridges. In cases where pairs of breakpoints 
cannot be uniquely assigned to a single bridge, multiple interpretations are tested in a subsequent step 
(see “Finalization of the graph”, below) 
 
Evaluation of graph cycles 
 
In some cases, PXY is extremely small – for instance, when breakpoints from separate fusions 
map within several hundred base pairs of one another – and the breakpoints clearly did not originate 
independently. However, borderline cases often arise where PXY is not sufficiently small to reject the 
independent model for two breakpoints unequivocally. In such cases, additional evidence that 
rearrangements were generated coordinately can be obtained by considering sets of breakpoints whose 
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nodes on the graph are contained within cycles (paths along edges that begin and end at the same 
node). 
Each cycle is evaluated under the independent breakpoint model based on PXY values for 
adjacent breakpoints within the cycle (Figure S3.3A). Specifically, all possible scenarios are considered 
by which one or more rearrangements within the cycle could have arisen independently. For example, 
three rearrangements involving six breakpoints in a hypothetical cycle (Figure S3.3B) could have arisen 
by the following (non-mutually exclusive) scenarios, where subscripted numbers in parentheses denoted 
rearrangements that occurred independently: 
 
{H(1)23, H(2)13, H(3)12, H(1)(2)(3)} 
 
This set of scenarios represents the independent model for the cycle, which encompasses all alternative 
possibilities to the breakpoints in the cycle arising coordinately (H123). 
ChainFinder considers the probability of detecting the independently generated breakpoints under 
each scenario within the observed distance of each other. Each scenario in the independent model 
requires that two or more pairs of adjacent breakpoints from separate rearrangements arise 
independently, in order to “split” the cycle into two or more separate events. Each such scenario can be 
expressed in terms of combinations of PXY values from edges within the cycle corresponding to adjacent 
breakpoints (i.e., Pab, Pcd and Pef; Figure S3.3B) 
 
{(Pab Pcd), (Pab Pef), (Pcd Pef), (Pab Pcd Pef)} 
 
As shown in Figure S3.3B, all scenarios involving three or more independent events require the co-
occurrence of two or more scenarios involving only two events. Therefore, rejecting all scenarios involving 
only two events is sufficient to reject the independent model overall for the cycle. To assess all scenarios 
involving two independent events, ChainFinder tests the pairwise products of all PXY values within a cycle 
(corresponding to all two-event scenarios) with control of the family-wise error rate (FWER; (Holm, 1979)) 
at 10-2 across all scenarios. Control of the FWER ensures that, if the independent model is rejected for a 
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cycle, there is a 1% chance that one or more of the independent rearrangement scenarios for the 
corresponding cycle were mistakenly rejected. All cycles for which the independent model is rejected are 
linked within a chain.  
 
Finalization of the graph 
 
Finally, the graph is refined by considering deletion bridges that could not be uniquely assigned. 
Although a single deletion bridge may exist that connects two breakpoints, frequently multiple 
interpretations are possible due to overlapping regions of deletion from separate alleles or distinct tumor 
subclones. In these cases, a single choice must be made from a set of mutually exclusive possible 
bridges. Bridges are mutually permissible only if the following conditions are met: 
 
1. The bridges do not share the same breakpoints at either deletion segment boundary 
2. If the bridges overlap, the deletion segment in the region of overlap must demonstrate a 
consistently lower copy number than segments outside the region of overlap. 
 
ChainFinder tests permutations of mutually permissible bridges to find the combination that 
incorporates the most breakpoints into deletion bridges, because this solution best reconciles the copy 
number and rearrangement data. If a unique valid combination of bridges exists that maximizes the 
number of breakpoints in deletion bridges, the bridges are accepted and any distinct chains that they link 
are combined. If multiple optimal interpretations exist, only bridges that are included in all of these 
interpretations are kept.  
The graph is finalized by removing any edge between neighboring breakpoints for which the 
independent-generation model could not be rejected. In addition, deletion bridge edges are retained in the 
graph only if the breakpoints on either end of the deletion arose non-independently (e.g., within a cycle).  
  
Evaluation of genes disrupted in chains 
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 Once chains have been assigned, a list of genes disrupted in each chain is compiled. Genes are 
included if they fall at least partially within a deletion bridge in the chain or within 10kb of a copy-neutral 
rearrangement in the chain. Circos plots are generated in which all rearrangements in a given chain are 
depicted in the same color (e.g., Figure 3.2B).  
 
Assessment of false-positive rate with simulated tumor genomes 
 
 In order to test the false-positive rate of ChainFinder, we created “scrambled” tumor genomes by 
simulating the independent accumulation of rearrangements based on observed data. For each tumor, 
ten “scrambles” were created that combined rearrangements from other tumors. Each scramble 
contained the same number of rearrangements as the corresponding sequenced tumor. Any two 
rearrangements were combined in a scramble only if they were not part of the same chain from the same 
sequenced tumor. The scrambles served as “true negative” cases in which all rearrangements were 
generated independently, while preserving genome-position specific influences on breakage and fusion, 
since the data are drawn from observed rearrangements. Copy number profiles were simulated based on 
observed data as well. Segments of copy number alteration were generated that maintained (1) the 
number of breakpoints at the boundaries of potential deletion bridges and (2) the overall ratio of copy 
number gains to losses. The simulated rearrangement and copy number data were profiled with 
ChainFinder, and the proportion of breakpoints assigned to a chain was compared between observed and 
simulated data. 
For each sequenced tumor, we also created ten simulations matched for rearrangement number 
and chromosomal connectivity. The rearrangement breakpoints were further matched to observed data 
with respect to (1) sequence coverage, (2) guanine and cytosine content of local sequence, (3) 
expression levels of nearby genes, (4) replication timing of DNA and (5) reference genome distance 
between breakpoints for intrachromosomal rearrangements (within 5%). Coverage was matched within 5x 
to the coverage near the observed breakpoint. Suitable locations for simulated breakpoints were identified 
by creating bins for the values of parameters (2) through (5) for each chromosome, and randomly 
choosing a location that falls within the same bin as the corresponding observed breakpoint. For each 
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feature (e.g., GC content), we created bins containing the bottom and top fifth percentiles across the 
chromosome. We then split the middle 90% evenly into three additional evenly spaced bins. Copy 
number profiles were simulated such that breakpoints at edges of deletion segments were preserved. In 
most cases where ChainFinder identified chains within simulated tumors, the simulations were too 
restrictive, so that the only matched location for a set of rearrangements in a chain was near to the 
location where they were observed. 
 
Quantification of gene expression near rearrangement breakpoints 
 
Expression was quantified in terms of gene-level FPKM (Fragments Per Kilobase of transcript per 
Million mapped reads) values from 16 prostate tumor transcriptomes using CuffLinks (Trapnell et al., 
2012). The transcription levels near rearrangements were estimated from median values of log10 
(1+FPKM) across the tumor transcriptomes in 10kb windows on either side of the breakpoint. Where this 
window overlapped multiple genes, the largest FPKM value was used. For the analysis shown in Figure 
3.4D, the statistical enrichment of chained breakpoints near highly expressed DNA in ETS-positive 
tumors was robust to exclusion of the TMPRSS2 and ERG loci from expression level estimates.  
 
Assessment of nuclear proximity of fused loci from Hi-C data 
 
We sought to determine whether breakpoints involved in structural rearrangements are in close 
physical proximity in nuclei in which these breakpoints have not yet occurred. For this, we used filtered 
chromatin interaction data (Hi-C) from experiments performed in prostate epithelial cells (RWPE1) stably 
expressing a GFP reporter (RWPE1-GFP) (Rickman et al., 2012). To determine whether a set of 
breakpoint pairs are in close proximity, we defined a 1Mb window centered on each breakpoint and 
counted the Hi-C reads connecting the two windows for all breakpoint pairs. The average Hi-C read 
counts were determined separately for chained rearrangement breakpoints and for breakpoints that were 
not assigned to a chain for comparison. Rearrangements were further subdivided by ETS-status of the 
tumor in which they were observed. 
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We then compared the observed average Hi-C count to Hi-C counts that would be observed by 
chance if the breakpoint pairs were randomly distributed on the genome. We generated random sets of 
breakpoints matched to the observed breakpoints for intra-chromosomal distances, chromosomal 
distribution and short read mappability. We again defined 1Mb windows centered in the random 
breakpoints and counted Hi-C reads connecting each pair of simulated breakpoints. We repeated this 
analysis 1,000 times to generate a null distribution of average Hi-C read counts for random breakpoint 
pairs. To generate a p-value, we counted how many of the 1,000 sets of random breakpoints had an 
average Hi-C read count greater than or equal to the average read count for the observed breakpoints. Of 
note, only intra-chromosomal rearrangements were considered for this analysis, as inter-chromosomal 
breakpoints were supported by very few Hi-C reads even when considering large windows centered on 
the breakpoints. 
 
Breakpoint enrichment analysis 
 
Enrichment and depletion of breakpoints was assessed across the genome with respect to 
replication time, guanine/cytosine (GC) content and distance to transcribed genes. Observed distributions 
were compared to randomly generated distributions controlled for chromosome and coverage. First, 
nearby breakpoints (up to 2,500bp away) were consolidated into a single “event.” For each event, 
100,000 locations (one per iteration) were generated uniformly from all locations on the same 
chromosome having the same coverage. The genome was considered in the following bins: low GC (0-
36%], medium GC (36%-45%] and high GC (45%-100%). Replication time was binned according to 
late/early ratio (Ryba et al., 2010) at (-∞,-0.8],(-0.8,0], (0,0.8],(0.8,∞). Changing the thresholds did not 
affect the essence of the results, other than losing sensitivity for very large or small bins (data not shown). 
For every bin we counted the number of breakpoints for both the observed breakpoints and the random 
breakpoints. All of these counts were used to compute nonparametric p-values (observed rates). 
Enrichment or depletion was determined by picking the lower of the one-sided p-values, and p-values 
were then corrected for multiple hypotheses by the Benjamini-Hochberg FDR procedure (Benjamini, 
1995). 
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An analogous procedure was used to detect enrichment near ChIP-Seq peaks (Yu et al., 2010), 
except that bins were substituted with windows spanning 50kb on either side of each peak.  
 
Quantification of tumor purity and subclonality 
 
Prior to sequencing, estimates of tumor purity and ploidy were derived from Affymetrix SNP6.0 
data using ABSOLUTE (Carter et al., 2012).  These estimates were used to select high purity samples for 
whole genome sequencing (median purity 70%; ploidy range 1.84 – 2.21; Table S3.1A).  
Analyses of tumor purity and subclonality from WGS data were performed by exploiting 
individuals’ genotypes at polymorphic loci within somatically altered regions of the genome, using 
considerations related to previously described methods (Carter et al., 2012; Landau et al., 2013; Nik-
Zainal et al., 2012). For each tumor sample included in the study, we estimated stromal DNA admixture 
and lesion clonality using CLONET (CLONality Estimate in Tumors; Prandi D. et al., manuscript in 
preparation). The approach behind CLONET and the MiSeq-based validation we performed are outlined 
hereafter.  
For a tumor sample TS containing a mixture of NTS normal (diploid) cells and TTS tumor cells, the 
percentage of admixed normal cells is:  
 
 
 
Based on the above equation, the admixture can be estimated from sequencing reads covering a site of 
hemizygous deletion s as: 
 
 
 
where βs(TS) is the proportion of reads at locus s that originated from normal cells in TS. 
!"# !" = ! !!"!!" !+ !!!" 
!"#! !" = ! !!(!")2− !!!(!") 
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In order to calculate Adm(TS), we first selected informative heterozygous SNPs within regions of 
somatic deletion that were identified from copy number array data. For each hemizygous deletion H, we 
considered the distribution of the allelic fractions (i.e., the fraction of reference sequence reads) from 
selected SNPs within H. Using “particle swarm optimization” (Kennedy, 1995) we calculated a composite 
value βH(TS) for the deleted region that best accounted for the observed distribution of allelic fractions at 
each heterozygous SNP s across the region. For every deletion, a value Adm.apparentH(TS) was 
computed that describes the apparent admixture at that locus. Adm.apparentH(TS) reflects both stromal 
admixture and potentially subclonal lesions that increase the apparent level of normal DNA at that locus. 
For each hemizygous somatic deletion H, the values of Adm.apparentH(TS) were grouped if the difference 
between the values could be explained by the estimation error determined by simulation-based error 
estimations. The smallest mean value of Adm.apparentH(TS) across a set of grouped deletions was taken 
as the candidate value of Adm(TS).  
 Estimates of cancer DNA purity by this procedure are listed in Table S3.1 and compared to 
estimates from the same tumors by ABSOLUTE run on SNP array data. The estimates were highly 
consistent across the samples (R2 = 0.99; p < 10-4) with the exception of two samples (PR-
STID0000002682 and PR-07-360), where stromal admixture was detected in WGS data but not SNP 
array data. 
We analyzed the clonality of gene deletions based on normalized log2 ratios of tumor and normal 
WGS sequence coverage, after correction for the estimated normal DNA admixture in tumor samples. 
Deletions where Adm and Adm.apparentH differ beyond the error estimation are potential sub-clonal 
lesions. We estimated the percentage of tumor cells that harbor a somatic hemizygous deletion H, i.e., 
the clonality of H, as: 
 
 
 
In the case of a 100% clonal hemizygous somatic deletion H the value of ClonalityH(TS) is 1, as 
Adm.apparentH(TS) equals Adm(TS); otherwise ClonalityH(TS) is less than 1. In the presence of high 
coverage, small variations in ClonalityH(TS) can demonstrate differences in sub-clonality along a 
!"#$%"&'(! !" = !1− !!"#.!""!#$%&!(!")1− !"#(!")  
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continuous scale. Here, in order to avoid false positive calls for borderline subclonality, we adopted a 
conservative approach and only considered two classes of deletions: clonal (ClonalityH(TS) ≥ 0.8) and 
subclonal (ClonalityH(TS) < 0.8). After Adm was calculated,we executed a similar procedure to estimate 
the clonal status of somatic homozygous deletions and point mutations.  
The sensitivity of clonality detection depends upon the number of heterozygous SNPs within a 
deletion of interest and the depth of sequence coverage at these SNPs. We evaluated the uncertainty in 
clonality estimates as a function of these parameters by randomly sampling 1,800 simulations and 
averaging the difference between the true clonality and computed clonality for a given coverage and 
number of SNPs (Table S3.6). To ensure robust clonality calls, we considered only deletions with 20 or 
more informative SNPs with average sequence coverage of 20x (corresponding to a 5.4% estimation 
error). Table S3.7 lists the percentage of tumor cells found to harbor a specific lesion together with the 
associated uncertainty range. 
 
Validation of clonality estimates 
 
To assess our ability to estimate apparent DNA admixture from our WGS data, we generated 
independent validation data for a set of 18 aberrant genes with four heterozygous SNPs each from seven 
tumor samples by PCR and deep sequencing (>65,000x coverage). The deep coverage provided a 
precise estimate of the ratio of alleles at SNP sites. Figure S3.6A compares the local apparent DNA 
admixture for the 18 genes computed using WGS data to the estimates computed using deep sequencing 
data (R2 = 0.85, p = 3.55 x 10-8). The contingency table inset in Figure S6A demonstrates agreement 
between WGS- and deep sequencing-based calls of clonality status (Cochran test, p-value = 1).  
 
Additional statistical analyses 
 
Quantitative comparisons of groups (e.g. numbers of rearrangements or SCNAs) were conducted 
with the rank-sum Mann-Whitney test, unless indicated otherwise. Box plots indicate median values and 
middle quartiles. 
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CHAPTER 4 
 
Transcriptional effects of prostate cancer-associated SPOP 
mutations and CHD1 inactivation 
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Introduction 
 
The genomic analyses of prostate cancer described in the preceding chapters have identified 
several genomic alterations that occur primarily or exclusively in ETS fusion-negative (ETS-) prostate 
tumors. In particular, mutation of the ubiquitin ligase subunit gene SPOP is strictly mutually exclusive with 
ETS gene fusions. Similarly, the chromatin modifying enzyme gene CHD1 is deleted or rearranged 
primarily in ETS- tumors that also harbor SPOP mutations. These observations suggest that SPOP 
mutation and deletion of CHD1 may contribute to prostate carcinogenesis in a distinct molecular subset of 
ETS- prostate cancers. In vitro studies have demonstrated that inactivation of CHD1 and mutation of 
SPOP lead to invasive and morphological changes (Barbieri et al., 2012; Huang et al., 2011); however 
the oncogenic mechanisms engaged by these perturbations are unclear.  
  In order to study the consequences of SPOP mutation and CHD1 deletion, we assessed the 
transcriptional profiles of prostate epithelial cells upon expression of mutant SPOP or knock-down of 
CHD1. We employed the LHMAR prostate epithelial cell line, which expresses large T antigen, hTERT, c-
Myc and the androgen receptor. While LHMAR cells lack tumor-forming ability when injected 
subcutaneously into nude mice, they can be rendered oncogenic by overexpression of oncogenes such 
as H-Ras or the PI3-Kinase subunit p110α (Berger et al., 2004). LHMAR cells therefore represent a 
“partially transformed” cellular model for prostate oncogenesis that is useful for assessing the 
transforming effects of somatic DNA alterations observed in human tumors.  
 Given the postulated rolls in transcriptional regulation of SPOP and CHD1 (Gaspar-Maia et al., 
2009; Kwon et al., 2006; Li et al., 2011), we hypothesized that SPOP mutation and CHD1 inactivation 
could induce transcriptional changes in LHMAR cells that reflect the molecular pathways engaged by 
these events in prostate cancer. We therefore used transcriptome sequencing (RNA-Seq) to profile gene 
expression in LHMAR cells with knock-down of CHD1 or expression of prostate cancer-associated SPOP 
mutant alleles. This chapter describes our analysis of signatures associated with these perturbations and 
discusses mechanisms by which these events may drive ETS- prostate cancer. 
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CHD1 inactivation activates cellular DNA damage responses 
 
 To assess the effects of CHD1 inactivation in prostate epithelial cells, we suppressed CHD1 
expression with three independent short hairpin RNAs (shRNAs) targeting non-overlapping regions of the 
gene. Knock-down was verified by Western blot (Figure S4.1). We performed RNA-seq and used CuffDiff 
2.0 (Trapnell et al., 2012) to assess expression changes in 8,581 genes upon CHD1 knock-down in 
LHMAR cells compared to a non-targeting control hairpin. All three hairpins caused largely concordant 
changes in transcription. For example, the top 5th percentiles of up- and down-regulated genes, 
overlapped significantly across the hairpins (Figure 4.1, left, p < 10-4 for each pair-wise comparison). 
Similarly, significant overlap was observed among genes that were up- or down-regulated at least two-
fold by each hairpin as well (Figure 4.1, right).  
We used gene set enrichment analysis (GSEA; (Subramanian et al., 2005)) to search for curated 
gene sets or oncogenic expression signatures that were significantly up- or down-regulated with CHD1 
suppression. Eighteen gene sets were significantly overexpressed upon knock-down of CHD1 at a false 
discovery rate (FDR) of < 10-4 (Table 4.1). Strikingly, the majority of up-regulated gene sets (13/18) 
pertained to cellular DNA damage response and p53 signaling (Figure 4.2). Previous studies have 
suggested a role for CHD1 in maintaining genomic stability (Huang et al., 2011; Liu et al., 2012) and 
prostate tumor genomes with deletion of CHD1 demonstrate a significant excess of chromosomal 
rearrangements (Chapter 3; Baca et al., 2013). Therefore, inactivation of CHD1 may induce DNA damage 
or prevent repair of DNA double strand breaks (DSBs), perhaps as a consequence of aberrant chromatin 
compaction or impaired access of DSB repair machinery to heterochromatin. Along these lines, 
inactivation in the mouse germline of Chd2, a closely related homolog, disrupts DSB repair and confers 
susceptibility to leukemias. Thus, CHD1 loss might promote tumor growth by facilitating the inactivation of 
additional tumor suppressor genes. This hypothesis will need to be explored experimentally in further 
detail, but is in line with the observation that CHD1-deleted tumors are enrichmed with other recurrent 
DNA deletions, such as loss of PTEN and CDKN1B (Chapter 3, Figure S3.4). 
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Figure 4.1. Knock-down of CHD1 with three independent hairpins alters the expression of 
overlapping genes 
The overlap of transcriptional responses upon CHD1 knockdown by each of three hairpins was assessed 
from RNAseq data using CuffDiff 2.0. LHMAR cells with a non-targeting hairpin served as a comparator. 
Significant overlap was observed between the top and bottom fifth percentiles of up- and down-regulated 
genes with each hairpin. Similar overlap was evident in genes that were up- or down-regulated by twofold 
compared to the non-targeting hairpin control cells. 
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Table 4.1. Gene sets related to DNA damage and p53 signaling are up-regulated with knock-down 
of CHD1  
Expression changes were averaged across LHMAR cell lines with CHD1 knock-down by three 
independent hairpins compared to control shRNA. Gene set enrichment analysis was used to identify 
gene sets that are significantly up-regulated with CHD1 knock-down. All gene sets with FWER p-values 
and FDR q-values < 10-4 are listed.  
 
 
 
 
 
 
Gene set Genes 
Genes in 
enrichment signal 
Normalized 
enrichment score 
FDR q-
value 
FWER 
p-value 
WARTERS_RESPONSE_TO_IR_SKIN 48 34 3.14 < 10-4 < 10-4 
SMIRNOV_RESPONSE_TO_IR_6HR_UP 118 60 3.11 < 10-4 < 10-4 
PID_P53DOWNSTREAMPATHWAY 97 46 2.98 < 10-4 < 10-4 
KERLEY_RESPONSE_TO_CISPLATIN_UP 34 26 2.81 < 10-4 < 10-4 
WARTERS_IR_RESPONSE_5GY 26 17 2.74 < 10-4 < 10-4 
SCHAVOLT_TARGETS_OF_TP53_AND_TP63 14 13 2.56 < 10-4 < 10-4 
DER_IFN_GAMMA_RESPONSE_UP 59 27 2.54 < 10-4 < 10-4 
SANA_TNF_SIGNALING_UP 42 20 2.51 < 10-4 < 10-4 
GHANDHI_DIRECT_IRRADIATION_UP 46 26 2.50 < 10-4 < 10-4 
DER_IFN_ALPHA_RESPONSE_UP 59 23 2.47 < 10-4 < 10-4 
GENTILE_UV_LOW_DOSE_UP 23 11 2.46 < 10-4 < 10-4 
BRACHAT_RESPONSE_TO_CAMPTOTHECIN_UP 24 12 2.46 < 10-4 < 10-4 
BRACHAT_RESPONSE_TO_METHOTREXATE_UP 19 10 2.44 < 10-4 < 10-4 
KIM_GLIS2_TARGETS_UP 33 16 2.41 < 10-4 < 10-4 
BRACHAT_RESPONSE_TO_CISPLATIN 18 9 2.41 < 10-4 < 10-4 
PHONG_TNF_TARGETS_UP 39 22 2.40 < 10-4 < 10-4 
ONGUSAHA_TP53_TARGETS 26 12 2.37 < 10-4 < 10-4 
RPS14_DN.V1_UP 54 27 2.37 < 10-4 < 10-4 
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Figure 4.2. GSEA enrichment plots showing up-regulation of gene sets related to DNA-damage 
response and p53 signaling  
FDR q-values are indicated for the enrichment of each gene set.  
 
Exemplary gene sets up-regulated with CHD1 knock-down 
q < 10-4 q < 10-4 
q < 10-4 q < 10-4 
 95	  
 
SPOP mutations activate transcriptional programs related to invasion, TGF-
β signaling and polycomb repression 
 
 We also used the LHMAR prostate epithelial cell line to probe the effects of SPOP mutation on 
cellular transcriptional output. SPOP mediates the ubiquitination of several transcriptional regulators such 
as DAXX and SRC3 (Kwon et al., 2006; Li et al., 2011) and SPOP mutations often occur in the absence 
of oncogenic lesions in prostate cancer genes such as TP53 or PTEN (Chapter 2). We therefore 
reasoned that SPOP mutation might activate oncogenic transcriptional programs. Furthermore, we 
hypothesized that distinct prostate cancer-associated SPOP mutations would exert similar effects, given 
their clustered distribution within the protein substrate binding pocket (Chapter 2). We therefore used 
RNA-Seq to assess whether two prostate cancer-associated SPOP mutants (F133L and Y87N) induce 
concordant changes in gene expression compared to wild-type SPOP.  
 To determine whether the two SPOP mutants had similar effects on transcription in prostate 
epithelial cells, we compared sets of genes with altered expression in both mutant-expressing cell lines 
according to our CuffDiff 2.0 analysis. We found significant overlap of genes up- or down-regulated by 
two-fold, or genes within the top fifth percentiles of differentially expressed genes (Figure 4.3). These 
results suggest that expression changes associated with SPOP mutation do not solely reflect “noisy” 
transcripts, and that the two mutants may have similar consequences at the transcriptional level.  
Our differential expression analysis pointed toward several cellular processes and pathways on 
which mutant SPOP might impinge in prostate cancer. Using GSEA, we identified 152 gene sets that 
were significantly up-regulated with mutant SPOP at an FDR q-value < 10-4 (Table 4.2). Many of these 
gene sets could be grouped into shared cancer-related pathways or processes. For example, multiple 
gene sets were enriched pertaining to cellular invasion and epithelial to mesenchymal transition (EMT) 
(Acloque et al., 2009). Additionally, TGF-β signaling pathways (which mediate invasive growth in several 
cancers (Elliott and Blobe, 2005)) were up-regulated. These findings are consistent with the observation  
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Figure 4.3. Two prostate cancer-associated SPOP mutations induce expression of an overlapping 
set of transcripts in prostate epithelial cells  
Differentially regulated genes were identified by CuffDiff 2.0 analysis of RNAseq data from SPOP mutant 
(F133L and Y87N) and SPOP wildtype-expressing LHMAR cells. To assess the overlap of transcriptional 
responses between the two SPOP mutants, we identified genes that were up- or down-regulated by either 
mutant compared to wild-type SPOP. 
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Table 4.2. SPOP mutation induces transcriptional changes related to cell invasion, polycomb 
repression, TGF-β signaling and Wnt/β-catenin signaling 
Enriched gene sets were identified by GSEA analysis of the average changes in gene expression with 
SPOPF133L and SPOPY87N compared to wild-type SPOP. Selected gene sets with FDR q-values < 10-4 are 
depicted and grouped by common molecular pathways or processes. 
 
 
 
 
 
 
Gene set Genes 
Genes in 
enrichment signal 
Normalized 
enrichment score FDR q-value FWER p-value Associated pathway(s) 
GU_PDEF_TARGETS_UP 45 23 2.33 < 0.001 < 0.001 EMT/invasion 
KEGG_CELL_ADHESION_MOLECULES_CAMS 35 26 2.26 < 0.001 < 0.001 EMT/invasion 
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP 123 70 2.68 < 0.001 < 0.001 EMT/invasion 
KEGG_ECM_RECEPTOR_INTERACTION 35 25 2.37 < 0.001 < 0.001 EMT/invasion 
ROZANOV_MMP14_TARGETS_UP 129 46 2.30 < 0.001 < 0.001 EMT/invasion 
WU_CELL_MIGRATION 90 48 2.29 < 0.001 < 0.001 EMT/invasion 
ANASTASSIOU_CANCER_MESENCHYMAL_TRANSITION_SIGNATURE 25 20 2.27 < 0.001 < 0.001 EMT/invasion 
REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION 29 24 2.17 < 0.001 0.002 EMT/invasion 
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN 299 116 2.16 < 0.001 0.003 EMT/invasion 
JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_UP 38 20 2.13 < 0.001 0.006 EMT/invasion 
PID_INTEGRIN1_PATHWAY 34 25 2.33 < 0.001 < 0.001 Integrin 
REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS 33 20 2.30 < 0.001 < 0.001 Integrin 
PID_INTEGRIN3_PATHWAY 26 17 2.27 < 0.001 < 0.001 Integrin 
MEL18_DN.V1_UP 64 46 2.79 < 0.001 < 0.001 Polycomb repressive complex 
BMI1_DN_MEL18_DN.V1_UP 63 42 2.70 < 0.001 < 0.001 Polycomb repressive complex 
BMI1_DN.V1_UP 69 47 2.67 < 0.001 < 0.001 Polycomb repressive complex 
WIEDERSCHAIN_TARGETS_OF_BMI1_AND_PCGF2 35 24 2.36 < 0.001 < 0.001 Polycomb repressive complex 
KONDO_EZH2_TARGETS 73 32 2.13 < 0.001 0.006 Polycomb repressive complex 
NUYTTEN_EZH2_TARGETS_UP 485 204 2.13 < 0.001 0.007 Polycomb repressive complex 
PLASARI_TGFB1_TARGETS_10HR_UP 75 35 2.38 < 0.001 < 0.001 TGFβ 
VERRECCHIA_DELAYED_RESPONSE_TO_TGFB1 26 16 2.31 < 0.001 < 0.001 TGFβ 
VERRECCHIA_EARLY_RESPONSE_TO_TGFB1 44 26 2.29 < 0.001 < 0.001 TGFβ 
LABBE_TGFB1_TARGETS_UP 46 24 2.22 < 0.001 < 0.001 TGFβ 
TGFB_UP.V1_UP 64 23 2.14 < 0.001 0.005 TGFβ 
SANA_TNF_SIGNALING_UP 37 23 2.40 < 0.001 < 0.001 TNF 
PHONG_TNF_RESPONSE_NOT_VIA_P38 191 87 2.35 < 0.001 < 0.001 TNF 
ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_UP 82 42 2.26 < 0.001 < 0.001 TNF 
PHONG_TNF_RESPONSE_VIA_P38_PARTIAL 85 49 2.19 < 0.001 0.001 TNF 
PHONG_TNF_TARGETS_UP 35 25 2.19 < 0.001 0.001 TNF 
ONDER_CDH1_SIGNALING_VIA_CTNNB1 39 23 2.44 < 0.001 < 0.001 Wnt/β-catenin 
ONDER_CDH1_TARGETS_2_UP 119 50 2.34 < 0.001 < 0.001 Wnt/β-catenin 
LABBE_TARGETS_OF_TGFB1_AND_WNT3A_UP 51 26 2.22 < 0.001 < 0.001 Wnt/β-catenin; TGFβ 
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that expression of mutant SPOP, but not wild-type SPOP, increases the invasion of prostate cancer cell 
lines (Chapter 2).  
Several pathways related to known or putative SPOP substrates were enriched as well. For 
example, polycomb repressive complex (PRC) signature genes were overexpressed in the setting of 
mutant SPOP, including targets of the BMI1 polycomb repressive protein (Table 4.2). This finding may be 
noteworthy given that BMI1 is a substrate of the SPOP-CUL3 ubiquitin ligase complex, and BMI1 is a key 
regulator of prostate stem cell self-renewal (Lukacs et al., 2010). Additionally, we recently identified the 
zinc finger protein WIZ as a potential SPOP substrate relevant to prostate cancer using a mass 
spectrometry-based screening approach. In LHMAR cells, F133L and Y87N mutant SPOP alleles 
significantly inhibit the ubiquitination of this protein, while wild-type SPOP increases ubiquitinated WIZ 
levels (J.P. Theurillat et al., manuscript in preparation). WIZ participates in the euchromatic histone H3K9 
methyl-transferase complex with C-terminal binding protein (CtBP) (Ueda et al., 2006), which may 
regulate transcription of genes involved in Wnt/β-catenin signaling, EMT and stem cell maintenance (Di et 
al., 2013; Fang et al., 2006). Both CtBP and Wnt/β-catenin related pathways were up-regulated with 
expression of mutant SPOP. Furthermore, analysis of human tumor RNA-Seq data from 16 cases (two 
SPOP mutant and 14 SPOP wildtype) showed activation of CtBP target genes in SPOP mutant tumors. 
These observations raise the possibility that SPOP mutations might perturb CtBP signaling in human 
tumors via effects on ubiquitination of WIZ.  
 
Discussion and conclusion 
 
We have examined the transcriptional output of prostate epithelial cells upon inactivation of CHD1 
or expression of mutant SPOP to study how these perturbations may mediate oncogenesis in human 
prostate cancer. We observed transcriptional profiles suggestive of DNA damage and p53 signaling upon 
knock-down of CHD1, which may suggest that CHD1 loss facilitates the accumulation of abundant 
SCNAs and rearrangements seen in CHD1-deleted tumors. Likewise, expression of mutant SPOP  
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Figure 4.4. Enrichment plots of gene sets up-regulated with mutation of SPOP  
(A) Enrichment plots of selected gene sets up-regulated in LHMAR cell lines with SPOP mutant 
expression (see Table 4.2).  
(B) Both LHMAR cells (top) and human prostate tumor tissues (bottom) expressing mutant SPOP were 
assessed for up-regulation of genes that showed increased expression with knock-down of CtBP-1 in 
prostate cancer cell lines in a previous study (Wang et al., 2012).  
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q!<!10%4!
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appeared to activate specific transcriptional modules compared to wild-type SPOP. Analysis of enriched 
gene sets in prostate epithelial cells expressing mutant SPOP suggested that SPOP mutation may drive 
EMT- and invasion-related gene transcription, and may activate genes that are normally repressed by the 
polycomb repressive complex and CtBP complex.  
Overall, these results suggest that SPOP mutation and CHD1 loss dysregulate distinct molecular 
processes, and provide hypotheses for ongoing experimental studies. It should be emphasized that our 
transcriptome analyses provide only preliminary insight into oncogenic mechanisms, and are limited by 
several factors. First, it is not known whether the LHMAR cells reflect the pathophysiological cell of origin 
of human SPOP-mutant or CHD1-deleted prostate cancers. In addition, collaboration of other oncogenic 
alterations may be required to fully unmask the effect of cancer-associated SPOP mutations. 
Furthermore, it is not yet known whether the transcriptional changes observed with these perturbations 
are responsible for the outgrowth of SPOP-mutant or CHD1-deleted cancer cell clones in human tumors. 
Nonetheless, the results of these experiments highlight several avenues for experimental study. Ongoing 
experiments will leverage transgenic mouse models to corroborate our findings, and will assess larger 
sets of SPOP-mutant or CHD1-deleted tumors for the transcriptional changes observed in our LHMAR 
model.  
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Methods 
 
Cell culture 
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LHMAR cells were previously derived from primary prostate epithelial cells via stable expression 
of Large T antigen, hTERT, c-Myc and the androgen receptor (Berger et al., 2004). Three shRNA 
contstructs in the pLKO.1 vector targeting CHD1 were virally transduced into LHMAR cells. Two days 
after infection, cells were selected in puromycin until no viable cells remained in a non-infected control 
plate (two days). Cells were then cultured for 7 days in RPMI 1640 and 10 million cells per condition were 
snap frozen in liquid nitrogen. The non-silencing hairpin was ordered from Sigma (SHC002 Sigma 
MISSION pLKO.1-puro Non-Mammalian shRNA Control Plasmid DNA). CHD1-directed hairpins were 
obtained from The RNAi Constortium (http://www.broadinstitute.org/rnai/public/) and were designed to 
target the following CHD1 sequences:  
 
Hairpin 1: GCGGTTTATCAAGAGCTATAA  
Hairpin 3: GCGCAGTAGAAGTAGGAGATA 
Hairpin 4: GCAGTTGTGATGAAACAGAAT 
 
CHD1 knock-down was verified by western blot using goat polyclonal antibody (Novus Biological, NBP1-
00168).  
Wild-type and mutant SPOP constructs with a Kozac ACC-sequence were coned into the 
pCW107 plasmid with the mOrange fluorescence marker using Neh1 and Mlu1 restriction enzymes. 
100% infection efficiency was confirmed by fluorescence microscopy. SPOP expression was confirmed 
by western blot using rabbit polyclonal antibody (Abcam, ab81163). Cells were cultured for a week in 
RPMI 1640 and 10 million cells were snap frozen in liquid nitrogen. 
 
RNA-sequencing data generation 
 
RNA-Seq, including library synthesis, sequencing and data processing were performed as described in 
Chapter 4 (Methods). 
  
Analysis of differentially regulated genes and gene sets 
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We used CuffDiff 2.0 (Trapnell et al., 2012) to compare gene-level expression between cell lines. 
Transcript and gene annotations were obtained from Gencode Version 7 (http://www.gencodegenes.org). 
A “mask” file was used to exclude several categories of small RNA transcripts from consideration by 
CuffDiff 2.0, including transcripts annotated with “Mt_rRNA”, “Mt_tRNA”, “misc_RNA”, “rRNA”, “snRNA” or 
“snoRNA”. Additionally, genes annotated as “PUTATIVE” or “NOVEL” were excluded. In general, CuffDiff 
2.0 was configured to require a minimum of 200 reads from a gene to assess differential expression 
between conditions. For the analysis of CtBP1 knock-down signature enrichment, we decreased the 
minimum read requirement to 100 reads in order to increase the number of genes within the CtBP1 
knock-down gene set that could be assessed by CuffDiff 2.0.  
Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005) was used to assess 
enrichment of up- or down-regulated transcripts between cell lines. GSEA was applied to the list of 
transcripts assessed by CuffDiff 2.0 that was “pre-ranked” based on average change in expression 
between the compared conditions (e.g., CHD1 hairpin versus control hairpin or SPOP mutant versus wild-
type). Our GSEA analysis included all gene sets within MSigDB containing between 15 and 500 members 
under the categories “C2: curated gene sets” and “C6: oncogenic gene sets” (3,624 sets total). In 
addition, we constructed a custom gene set corresponding to potential CtBP1 targets from a list of genes 
that were up-regulated > 2-fold with knock-down of CtBP1 in DU145, PC3 and LNCaP prostate cancer 
cell lines in a previous study (Wang et al., 2012).  
 
Statistical analysis 
 
Two-sided p-values from Fisher’s exact tests are indicated for comparison of up- and down-regulated 
transcripts between cell lines.  
 
  
 
 
 
 
 
 
 
 
 
CHAPTER 5 
 
Conclusions and future directions 
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 The studies described in this thesis provide an early sketch of the landscape of somatic 
alterations in prostate cancer genomes. This research builds upon studies over the last two decades that 
have probed prostate tumor DNA at ever-finer resolution to uncover alterations that drive disease 
initiation, progression, and therapeutic resistance (Shen and Abate-Shen, 2010). By sequencing the 
protein-coding genes in a large panel of tumors, we were able to identify positive selection for mutations 
in genes that were not previously implicated in cancer, such as FOXA1, MED12 and SPOP. By analyzing 
entire genomes from a smaller tumor panel, we gained insight into the clonal evolution of prostate 
cancers and discovered that genomic rearrangements may accumulate in a highly inter-dependent 
manner.  
 
Novel putative prostate cancer genes implicated by tumor DNA sequencing 
 
 
 
 Our analysis of 112 prostate cancer exomes revealed novel significantly mutated genes that may 
point to important molecular processes in the pathogenesis of this disease. For example, recurrent 
mutations in the substrate-binding cleft of the SPOP ubiquitin ligase subunit may prevent turnover of 
oncogenic proteins by ubiquitin-mediated proteolysis. Along these lines, several instances of altered 
proteolytic homeostasis have been documented in prostate cancer. For example, overexpression of the 
Skp2 ubiquitin ligase promotes degradation of tumor-constraining proteins such as p27Kip1 (Carrano et al., 
1999; Yang et al., 2002). Additionally, the truncated form of ETV1 that is expressed in the context of the 
TMPRSS2-ETV1 fusion escapes COP1-mediated ubiquitination and degradation, and may thereby 
accumulate to pathological levels (Vitari et al., 2011). Similarly, the accumulation of certain oncogenic 
proteins might drive SPOP-mutant prostate cancer, if the documented SPOP mutations prevent substrate 
binding as predicted. 
The relevant targets of SPOP in prostate oncogenesis are not yet known. Several substrates of 
the SPOP-CUL3 complex have been identified, including the transcriptional repressor DAXX (Kwon et al., 
2006), the hedgehog pathway transcription factor Gli (Zhang et al., 2009) and the histone variant protein 
MACROH2A (Hernandez-Munoz et al., 2005). Experiments are underway to assess the proteome-wide 
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changes in protein ubiquitination induced by SPOP mutations, and may shed light on the drivers of 
SPOP-mutant cancer. Preliminary results from transcriptome-sequencing studies described in Chapter 4 
point to processes associated with invasion and metastasis as well as polycomb and TGF-β signaling, all 
of which have been implicated in prostate tumorigenesis (Ding et al., 2011; Lukacs et al., 2010; Ru et al., 
2012). As discussed in Chapter 2, a dominant-negative effect of SPOP mutations seems likely given the 
cluster of mutated residues in SPOP, the absence of missense mutations or bi-allelic inactivation, and 
previous knowledge that SPOP functions in a homo-dimeric complex (Zhuang et al., 2009). Therefore, 
elucidating relevant SPOP substrates may not only inform our understanding of prostate cancer biology, 
but may also point to therapeutic targets that are upregulated due to decreased proteolytic turnover.  
The transcription factor gene FOXA1 was another novel cancer gene implicated by this work. 
FOXA1 functions in prostatic development (Gao et al., 2005) and facilitates lineage-specific transcription 
by binding to DNA enhancer elements (Lupien et al., 2008). The recurrent mutations that cluster within 
DNA-interacting residues of FOXA1 may disrupt transcriptional regulation by this protein. FOXA1 adds to 
a growing list of prostatic developmental genes that are somatically altered in prostate cancer. Two well-
characterized examples include NKX3-1, a regulator of prostatic developmental transcription that is 
frequently deleted, and the androgen receptor, which coordinates androgen-mediated transcriptional 
programs and is mutated in castration-resistant disease. Collectively, these alterations suggest that 
prostate oncogenesis involves the halted natural development and differentiation of prostate epithelial 
cells – a concept that has been explored in other cancers (Chou et al., 2010; Ferrero et al., 1982; Yang 
and Weinberg, 2008). Interestingly, FOXA1 mutations and NKX3-1 deletions were strictly clonal in our 
tumor panel, suggesting that they arise within a common ancestor of sequenced tumor cells and occur 
early in disease. These alterations might revert incipient prostate cancer cells into a de-differentiated 
state that renders them susceptible to subsequent oncogenic insults such as PTEN or CDKN1B 
inactivation (Chapter 3).  
 An important finding of our studies is that many genes underwent recurrent and/or oncogenic 
alterations in only a small subset of tumors. For example, several genes such as IDH1, HRAS, KDM6A 
revealed cancer-associated mutations in < 3% of samples (Chapter 2). Likewise, a number of potentially 
activating fusions were observed that could lead to overexpression of proto-oncogenic kinases (e.g., 
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CRKL-MAPK1 and NRF1-BRAF; Chapter 3), yet these events were only observed in a single tumor each. 
Thus, the distribution of driving lesions across prostate tumors may contain a long “tail” of infrequent 
events that are observed only once or twice among hundreds of tumors. An implication of this model is 
that large panels of tumors from diverse patient populations will need to be sequenced to identify 
additional significantly mutated genes. Therefore, ongoing large-scale cancer genome studies will likely 
prove fruitful for discovering rare driver mutations. In addition, burgeoning efforts to use tumor genomic 
information to guide clinical decisions may need to overcome the challenge of identifying patient-specific 
lesions that drive disease but are very rarely recurrent. A similar paradigm has emerged in non-small cell 
lung cancer. In this disease, oncogenic rearrangements of ALK and ROS1 are proving promising 
therapeutic targets (Camidge et al., 2012; Janne and Meyerson, 2012); however these lesions occur in 
roughly 3% and 2% of cases, respectively (Bergethon et al., 2012). Ultimately, both bioinformatics and 
experimental strategies may be required to identify infrequent, targetable driving lesions within a 
sufficiently short timeframe to benefit patient care. 
  
Molecular subtypes of prostate cancer and alternative paths of 
oncogenesis 
 
 Our studies add to a growing body of evidence that separable molecular subtypes of prostate 
cancer exist that harbor distinct sets of co-occuring genetic or epigenetic alterations. For example, we 
confirmed previous reports ERG rearrangement is associated with TP53 and PTEN lesions, as well as 
deletion or rearrangement of FOXP1 (Taylor et al., 2010). We observed that SPOP mutations are strictly 
mutually exclusive with ETS fusions, but co-occur with a distinct set of alterations such as CHD1 deletion, 
highlighting a distinct subclass of ETS-negative cancer. Previous studies have uncovered ETS-negative 
subclasses with distinctive transcriptional profiles. For example, roughly 10% of ETS-negative cancers 
appear to be driven in part by overexpression of the serine protease inhibitor gene SPINK1 (Tomlins et 
al., 2008). Similarly, tumors may be classified by expression profiles corresponding to ETS-driven 
transcription, stem cell-like signatures or activation of one of several other oncogenic pathways. These 
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classifications appear to portend different survival outcomes (Markert et al., 2011). Therefore, it could be 
fruitful to establish whether transcriptional profiles of ETS-negative tumors correspond to specific 
mutational subclasses, as the latter could be easier to assess reliably for clinical applications.  
 Our analysis of clonal evolution suggests that ETS gene fusions and SPOP mutations lead 
tumors down divergent pathways early in their development, because these alterations are strictly clonal 
and mutually exclusive. It may be worthwhile, therefore, to study whether these cancer groups are linked 
to different environmental or genetic risk factors or clinical behaviors. Previous studies comparing clinical 
outcomes of ETS-positive to ETS-negative tumors have given varying results depending on the 
populations compared (i.e., PSA-screened or not) and the endpoints assessed (PSA recurrence versus 
overall mortality) (Demichelis et al., 2007; Rubin et al., 2011; Saramaki et al., 2008). These studies may 
be aided by further stratification of tumors on a molecular genetic level to account for the genotypic 
variability of ETS-negative tumors.  
 
A model for transcription-associated DNA damage in ETS-positive prostate 
tumors 
 
 Our analysis of inter-dependent genomic rearrangements suggests that chromosomal 
abnormalities in prostate cancer may accumulate over a series of relatively few punctuated events 
(Chapter 3). This process, which we have termed “chromoplexy,” may be driven by different mechanisms 
in different genetic subclasses of cancers. For example, tumors with CHD1 disruption displayed an 
excess of DNA rearrangements and deletions. The breakpoints of these lesions were strongly enriched in 
gene-poor, late-replicating DNA distant from transcriptionally active chromatin. Our RNA-Seq studies of 
CHD1-depleted prostate epithelial cells (Chapter 4) suggested that CHD1 suppression induces similar 
transcriptional changes to genotoxic insults such as gamma irradiation or cisplatin treatment. Thus, CHD1 
disruption might increase the frequency or magnitude of chromoplexy events in a subset of incipient 
cancer cells, thereby promoting disruption of other cancer genes (Chapter 3) – a conjecture that will be 
addressed in future experimental studies.  
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 In contrast, chromoplexy in ETS-positive tumors produced distinctive patterns of structural 
alterations that may indicate a different generative mechanism. Chained rearrangements in ETS-
rearranged tumors frequently involved small clusters of breaks distributed across four or more 
chromosomes. Rearrangements in these tumors were somewhat enriched near actively transcribed DNA. 
A prior study from our lab indicated that some ETS-rearranged tumors showed enrichment of breaks near 
androgen receptor (AR) and ERG transcription factor binding sites (Berger et al., 2011), a finding that was 
replicated in this study. 
 The association of DNA breaks with active transcription led us to hypothesize that transcription-
coupled DNA damage may account for complex rearrangement chains in ETS-positive tumors. Several 
lines of experimental evidence have indicated that transcription can both engender transient DNA breaks 
and bring geographically distant foci into close proximity, allowing the formation of specific gene fusions. 
For example, the TMPRSS2 and ERG loci are brought into physical proximity by liganded AR, and the 
TMPRSS2-ERG fusion can be induced by concomitant irradiation or endonuclease activity of TOP2B, 
ORF2 or AID (Haffner et al., 2010; Lin et al., 2009; Mani et al., 2009). Similarly, active transcription and 
physical co-localization precedes the fusion of oncogenes involved in other cancers, such as anaplastic 
large-cell lymphoma, Burkitt’s lymphoma or chronic myeloid leukemia (Robbiani et al., 2008).  
 Our analysis of prostate cancer genomes suggests that such a process may underlie not only 
TMPRSS2-ERG fusions, but chromoplexy-associated rearrangements in general in ETS-positive tumors. 
By this model (Figure 5.1), genes throughout the genome that are regulated by the same transcription 
factor(s) (e.g., AR) are brought into close proximity at “transcription factories” (Cook, 2010). As 
transcription proceeds, DNA breaks are frequently generated and recognized by double strand break 
(DSB) repair machinery. Although such DSBs are usually repaired correctly, occasionally two broken 
DNA ends may be aberrantly joined in an unbalanced translocation. In this case, two DNA ends are left 
unrepaired and may fuse to additional DSB sites that arise nearby (Figure 5.1). This process could 
continue within a cell cycle until all broken ends are finally paired, resulting in a “closed chain” of 
rearrangements. Alternatively, if one or more broken DNA fragments are not re-ligated to a centromere 
prior to cell division, chains could result that are not “closed.” Most instances of chromoplexy would be 
detrimental to cell survival and proliferation. In rare cases, however, generation of an oncogenic fusion 
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Figure 5.1. Model for chromoplexy via transcription-associated DNA breaks at transcriptional 
hubs 
Closed chains of rearrangement breakpoints associated with chromoplexy could arise from DNA damage 
associated with transcription. Multiple genomic loci across distinct chromosomes (denoted by strands of 
different colors) may be brought into physical proximity at transcriptional hubs (“TH”, gray circles), for 
example, due to coordinate regulation by the androgen receptor or other transcription factors (1). Double-
strand breaks accumulating at transcription hubs could be recognized by double-strand break repair 
machinery (2). The aberrant repair of two broken loci in a non-reciprocal manner would leave unpaired 
DNA ends, that could aberrantly fuse to other DNA ends that arise within the same cell cycle (3). Thus 
multiple rounds of breaks and rearrangement could be “propagated” until the chain is closed by the last 
remaining free ends being fused to one another (step 4-9). 
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such as TMPRSS2-ERG or disruption of a tumor-suppressor gene such as PTEN could confer a selective 
advantage that drives the clonal expansion of a cancer cell. This model could be tested by inhibiting DSB 
repair in prostate epithelial cells in the presence and absence of stimulated AR transcription. The model 
would predict that chained rearrangements could be detected in the setting of AR activity by FISH or 
single-cell sequencing. If supported experimentally, this model could point to transcription-associated 
DSBs as a target for therapy or chemoprevention.  
 
Future directions: prostate cancer in the era of genomics-driven medicine 
 
High-throughput genomic profiling has advanced the understanding, prognostication and 
treatment of several tumor types. For example, identification of mutations in BAP1 in uveal melanoma 
(Harbour et al., 2010) or IDH1 in glioblastoma and acute myeloid leukemia (Mardis et al., 2009; Parsons 
et al., 2008) demonstrated the power of genome sequencing to pinpoint novel cancer-driving mutations. 
Risk-predictive transcriptional signatures have improved prognostication for patients with breast cancer 
(van 't Veer et al., 2002), while the mutational status of EGFR in non-small cell lung cancer predicts 
clinical response to inhibitors of this kinase (Paez et al., 2004). Prostate cancer may be similarly ripe for 
discovery of novel cancer genes and biomarkers as well, since genomic characterization of large cohorts 
of aggressive tumors has only recently become feasible. As a step in this direction, our exome 
sequencing study revealed that SPOP is among the most frequently mutated genes in primary tumors, 
though its role in cancer was heretofore unrecognized. Ongoing studies will likely identify additional 
mutations and rearrangements that occur infrequently but nonetheless promote oncogenic growth.  
Several hurdles must be overcome for genomic technologies to impact the clinical management 
of prostate cancer. For instance, biopsies produce scarce material for clinical genotyping and may not 
fully capture the relevant molecular heterogeneity within a tumor. Expression signatures have not yet 
demonstrated sufficient prognostic value to merit widespread use. In addition, recurrent genomic lesions 
identified thus far are largely not considered “druggable”.  
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These challenges can likely be surmounted by new approaches. For example, genomic 
characterization may identify opportunities to leverage synthetic lethality by inhibiting targets that are 
essential in the setting of a particular mutation, such as poly (ADP-ribose) polymerase in ETS-fusion 
positive prostate cancer (Brenner et al., 2011). The analysis of multiple samples from a primary tumor 
and perhaps from circulating tumor cells may allow aggressive tumor subclones to be identified. 
Ultimately, new paradigms for clinical trials may be required that incorporate cancer genomic information. 
In spite of these challenges, genomic profiling is likely to play an expanding role in the biological study of 
prostate cancer and eventually in the clinical management of this malignancy.   
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APPENDIX 1 
 
Supplemental tables 
 
 
The following tables are provided separately as Excel spreadsheets: 
Table S2.2. Exome sequencing statistic summaries  
Table S2.3. Somatic mutations in 112 primary prostate tumor-normal pairs  
Table S3.1. Clinical characteristics of genome-sequenced prostate tumors 
Table S3.2. Sequencing metrics of 57 prostate cancer whole genomes 
Table S3.3. Somatic DNA alterations in 57 prostate cancers 
Table S3.4. Outlier expression of rearranged genes 
Table S3.5. Summary of rearrangement chains 
Table S3.6. Clonality analysis of prostate tumor genomes 
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Table S2.1. Clinical characteristics of exome-sequenced primary prostate cancers 
 
 
 
Characteristic! Whole exome-sequenced tumors!
Age, years!
          Median (range)!
!
63!
!
(34 – 77)!
Pre-operative Serum PSA (ng/μL)!
          Median (range)!
!
7.8!
!
(2.7 – 31.5)!
Pathologic Stage, N %!
          Stage pT3 Total!
                    Stage pT2a!
                    Stage pT2b!
                    Stage pT2c!
          Stage pT3 Total          !
                    Stage pT3a!
                    Stage pT3b!
                    Stage pT3c!
!
44!
4!
1!
39!
68!
49!
18!
1!
!
39%!
4%!
1%!
35%!
61%!
44%!
16%!
1%!
Gleason Pattern (major + minor), N %*!
          Gleason 3+3!
          Gleason 3+4!
          Gleason 4+3!
          Gleason 4+4!
          Gleason 4+5!
!
13!
58!
29!
8!
4!
!
12%!
52%!
26%!
7%!
4%!
Percentage of Gleason Pattern 4 and 5, N %*!
          0-19%!
          20-39%!
          40-59%!
          60-79%!
          80-100%!
!
40!
23!
5!
12!
29!
!
36%!
12%!
5%!
11%!
26%!
TMPRSS2-ERG Fusion Status, N % †!
          Fusion-negative!
          Fusion with interstitial deletion!
          Fusion without interstitial deletion!
!
53!
34!
24!
!
48%!
31%!
22%!
* Gleason scores based on review of hematoxylin and eosin slides from site of tumor chosen for DNA 
extraction and sequencing!
†TMPRSS2-ERG fusion status assessed by fluorescence in situ hybridization (FISH)!
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Table S2.4. Mutation of PIK3CA and PTEN is enriched in locally advanced tumors.  
(A) Tumors are grouped based on stage and presence or absence of mutations in PIK3CA or PTEN. Only 
stage pT3 tumors displayed mutation in either gene (two-sided p = 0.011, Fisher’s exact test).  
(B) Mutations in PTEN or PIK3CA detected by exome sequencing. The hyper-mutated tumor, PR-00-
1165, was included in this analysis and contained two mutations in PTEN, presumably affecting separate 
alleles. Amino acids are numbered based on RefSeq protein ID NP_000305 for PTEN and NP_006209 
for PIK3CA. Instances of all substitutions have been documented previously in prostate cancer or other 
cancer types in the Cosmic database (http://www.sanger.ac.uk/genetics/CGP/cosmic/). *, nonsense 
mutation. 
 
 
 
Stage pT2! Stage pT3! Total!
PIK3CA/PTEN mutant:! 0! 9! 9!
PIK3CA/PTEN wild-type:! 44! 59! 103!
Total:! 44! 68! 112!
PTEN mutations:! Reported in Cosmic! PIK3CA mutations:! Reported in Cosmic!
K128N! Yes! p.H1047R! Yes!
R130Q! Yes! p.G118D! Yes!
Y336*! Yes! p.Q546P! Yes!
G129R! Yes! p.Y1021H! Yes!
R173H, R233*! Yes, Yes!
A!
B!
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Table S2.5. Mutations in significantly-mutated genes and other selected genes  
Substitutions in significantly mutated genes are documented at the transcript and protein level for exome-
sequenced samples. Annotations are based on the UCSC Genome Browser identifier listed in the left 
column beneath each gene symbol. The right-most four columns summarize expression data for each 
gene from the panel of 63 tumors profiled by transcriptome sequencing; “RNA” refers to the log10(RPKM + 
1) value for each transcript. All genes except for SCN11A and THSD7B are expressed at comparatively 
high levels in prostate tumors at the mRNA level. fs, frame-shift mutation; del, deletion; CV, coefficient of 
variation. 
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Table S2.6. Significantly mutated gene sets 
Curated gene sets representing canonical pathways were analyzed for enrichment of mutations in their 
constituent genes (SOM). Sets that are significantly mutated above a q-value of 0.05 (Benjamini-
Hochberg adjustment) are listed. 
 
 
Gene Set! No. mutations! No. tumors 
with a mutation!
B-H q-value! Genes in set mutated (no. tumors affected)!
SA_G1_AND_S_PHASES! 11! 10! 0.00033! CDKN1B(3), TP53(8)!
RBPATHWAY! 14! 13! 0.00033! ATM(3), CDC25A(1), MYT1(1), TP53(8), WEE1(1)!
P53HYPOXIAPATHWAY! 14! 13! 0.0048! ABCB1(2), AKT1(1), ATM(3), TP53(8)!
TERTPATHWAY! 9! 8! 0.0048! SP1(1), TP53(8)!
PLK3PATHWAY! 11! 10! 0.0062! ATM(3), TP53(8)!
IGF1MTORPATHWAY! 14! 13! 0.0072! AKT1(1), GSK3B(1), IGF1R(1), INPPL1(1), PIK3CA(4), PIK3R1(1), PTEN(5)!
ARFPATHWAY! 13! 12! 0.008! PIK3CA(4), PIK3R1(1), TP53(8)!
G1PATHWAY! 16! 14! 0.008! ATM(3), CDC25A(1), CDKN1B(3), GSK3B(1), TP53(8)!
G2PATHWAY! 17! 16! 0.011! ATM(3), CDC25A(1), EP300(1), MYT1(1), PRKDC(1), RPS6KA1(1), TP53(8), WEE1(1)!
CHEMICALPATHWAY! 16! 14! 0.011! AKT1(1), ATM(3), CASP3(1), CASP9(1), TLN1(2), TP53(8)!
PTENPATHWAY! 17! 16! 0.011! AKT1(1), BCAR1(1), CDKN1B(3), ILK(1), PIK3CA(4), PIK3R1(1), PTEN(5), SHC1(1)!
RNAPATHWAY! 9! 8! 0.011! DNAJC3(1), TP53(8)!
P53PATHWAY! 11! 10! 0.017! ATM(3), TP53(8)!
COMPLEMENT_ACTIVATION
_CLASSICAL!
10! 10! 0.017! C1QB(1), C1S(1), C3(3), C6(1), C8A(1), C9(2), MASP1(1)!
CLASSICPATHWAY! 9! 9! 0.018! C1QB(1), C1S(1), C3(3), C6(1), C8A(1), C9(2)!
COMPPATHWAY! 10! 10! 0.018! C1QB(1), C1S(1), C3(3), C6(1), C8A(1), C9(2), MASP1(1)!
HCMVPATHWAY! 10! 10! 0.018! AKT1(1), CREB1(1), MAP2K6(1), MAPK14(1), PIK3CA(4), PIK3R1(1), SP1(1)!
TELPATHWAY! 14! 13! 0.025! AKT1(1), EGFR(1), IGF1R(1), POLR2A(1), TEP1(1), TP53(8), XRCC5(1)!
ALTERNATIVEPATHWAY! 7! 7! 0.027! C3(3), C6(1), C8A(1), C9(2)!
CDC42RACPATHWAY! 8! 7! 0.027! ACTR2(1), PDGFRA(2), PIK3CA(4), PIK3R1(1)!
SA_PTEN_PATHWAY! 12! 11! 0.04! AKT1(1), ILK(1), PIK3CA(4), PTEN(5), SHC1(1)!
RACCYCDPATHWAY! 11! 11! 0.04! AKT1(1), CDKN1B(3), HRAS(1), PIK3CA(4), PIK3R1(1), RAF1(1)!
CELL_CYCLE_KEGG! 29! 28! 0.042! ATM(3), BUB3(1), CDC20(1), CDC25A(1), CDC6(1), CDH1(1), EP300(1), ESPL1(1), 
GSK3B(1), HDAC2(2), HDAC3(1), HDAC5(2), MAD1L1(1), MCM4(1), PRKDC(1), 
SMAD4(1), TP53(8), WEE1(1)!
IGF1RPATHWAY! 11! 11! 0.042! AKT1(1), HRAS(1), IGF1R(1), IRS1(1), PIK3CA(4), PIK3R1(1), RAF1(1), SHC1(1)!
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Table S2.7. SPOP mutations in multiple cohorts 
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Table S2.9.  Primer sequences 
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Table S2.10. BAC probes used for FISH 
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Figure S2.1. Depth and breadth of exome sequencing coverage  
(Center) Sequencing coverage across all sites targeted by hybrid capture. Each row represents a 
targeted exonic site; each column represents a tumor-normal pair. Coloring reflects the depth of 
sequencing coverage. White coloring indicates a minimum of 14 reads in the tumor and 8 reads in the 
normal.  
(Left) GC content across targeted sites (GC content is equal to the number of C or G nucleotides divided 
by the total number of nucleotides).  
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Figure S2.2. Overlap of sample profiling across platforms  
Exome sequencing was conducted on 112 tumor-normal pairs. A single highly-mutated tumor (PR-00-
1165) was excluded from subsequent analyses, except where otherwise indicated, leaving 111 pairs. 
RNA-sequencing was performed on 22 of the exome-sequenced tumors and 41 independent tumors. All 
but four of the 112 exome-sequenced tumors, plus an additional 61 tumors, were analyzed for copy 
number alteration by high-density SNP array (169 total). 
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Figure S2.3. Rates of somatic substitutions in prostate exomes  
(A) Number of somatic mutations per Mb sequenced across the cohort of tumors. A single primary tumor 
(PR-00-1165) harbored a large excess of mutations compared to other tumors (32.1 per Mb versus 1.4 
per Mb median in the remaining primary tumors, red). A prostate cancer metastasis sequenced but not 
reported here showed a similar extent of mutation (PR-18248; 29.0 mutations per Mb, red). The two 
highly mutated tumors contained the indicated alterations in mismatch repair genes.  
(B) Median number of non-synonymous and synonymous mutations across 111 exomes (the single 
hyper-mutated primary tumor PR-00-1165, with 997 mutations, is excluded).  
(C) Mutations per million sites sequenced for the most frequent mutation categories in the dataset. *CpG 
to T, C to T transversion at a CpG dinucleotide; *CpG to A/C/T, C to T transversion not in the context of a 
CpG dinucleotide; C to (G/A), mutation of C to G or A; A to mut, mutation of A; Indel, small insertion or 
deletion. 
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Figure S2.3 (continued) 
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Figure S2.4. Relative ability to detect mutations in subgroups of tumors  
(A-D) The allelic fraction (AF) values of mutations were used to assess the relative purity of cancer DNA 
in each tumor (SOM). AF is the number of reads supporting a mutant allele divided by the total number of 
reads covering the mutated site. (A) and (B), maximum mutant AF observed in each tumor, grouped by 
Gleason score and stage. The top fifth percentile of AF values was removed in each tumor to exclude 
values that were elevated due to copy number variation at mutated sites. (C) and (D), as in (A) and (B), 
but showing median AF values across all mutations for each tumor. The relative purity of cancer DNA as 
assessed by AF did not vary by pathological stage or Gleason score.  
(E) Maximum mutant AF correlated only moderately with the number of mutations detected, implying that 
detection of mutations in most tumors was not systematically limited by admixture of normal DNA.  
(F) Mutations per Mb sequenced in tumors grouped by source of paired normal DNA: peripheral blood 
(n=22) or non-cancerous prostate (n=89). No difference in mutation rates was observed between the two 
groups. Two-tailed p-values were calculated using the Mann Whitney test (two groups) or Kruskal-Wallis 
(multiple groups) test and the Spearman test for correlation. n.s., not significant. Statistical analysis was 
performed using GraphPad Prism. 
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Figure S2.4 (continued) 
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Figure S2.5. Mutational landscape across a spectrum of primary prostate cancers   
(A-D) Mutations per Mb of covered DNA sequence for 111 primary prostatic adenocarcinomas grouped 
by clinical parameters. The horizontal axes denote: (A) Gleason score (major pattern + minor pattern); (B) 
Percent of cancer with Gleason pattern 4 or 5 histology; (C) Pathological tumor stage, where T3 indicates 
extra-prostatic extension; (D) Presence or absence of the TMPRSS2-ERG fusion based on fluorescence 
in-situ hybridization (FISH). Mutation rates are higher in pT3 tumors but do not vary by Gleason pattern or 
TMPRSS2-ERG fusion status.  
(E) Fraction of mutations in each tumor that are C to T transitions at CpG sites.  
(F) Number of CpG to T transitions per million CpG sites. Both the number and proportion of CpG to T 
mutations is increased in TMPRSS2-ERG fusion positive tumors. Two-tailed p-values from the Mann 
Whitney test (two groups) or Kruskal-Wallis test (multiple groups) are indicated for each comparison. 
Statistical analysis was performed using GraphPad Prism. n.s., not significant. 
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Figure S2.5 (continued) 
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Figure S2.6. Expression levels of select mutated genes 
Significantly-mutated genes and selected genes listed in Table S2.5 were analyzed for level of transcript 
expression in the RNA-Seq dataset. The histogram shows the number of transcripts with a given value of 
log10 (RPKM+1) (where RPKM is the number of reads per kilobase of exon per million mapped sequence 
reads), binned by increments of 0.1. The RPKM provides an estimate of the relative expression of 
transcripts. Vertical lines indicate the percentile of log10(RPKM+1) among all transcripts. Listed genes are 
grouped based on their percentile of log10(RPKM+1) value: <40%, 40-60%, 60-80% and >80%. Values 
and percentiles are listed in Table S2.5.  
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Figure S2.7. Laser capture microdissection and sequencing of MED12  
(Top) Laser capture micro-dissection and Sanger sequencing was performed on MED12-mutant tumors 
to determine whether the mutations were present in epithelial or stromal cells. H&E slide of frozen tissue 
from a MED12-mutant tumor (PR-3026) showing adenocarcinoma and surrounding mixed stroma. Exome 
sequence reads demonstrated an L1224F mutation in exon 26 of MED12. Laser capture micro-dissection 
was performed to separate epithelium from stroma (inset).  
(Bottom) The selected stromal area (dashed line, left) demonstrates wild-type MED12 sequence by 
Sanger sequencing, while the dissected tumor gland (dashed line, right) exhibits the L1224F mutation. 
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Figure S2.8.  Mutations in SPOP in RNA-Seq data and Sanger sequencing of genomic tumor DNA  
In each panel, RNA-seq reads mapping to SPOP Exon 6 or 7 from the indicated sample are shown. 
Coordinates (hg18) on chromosome 17 are at the top of each panel, and the reference genome (hg18) 
and wild-type SPOP amino acids are displayed at the bottom. Each horizontal gray bar represents one 
read. Nucleotide mismatches with respect to the reference genome in each read are highlighted by 
displaying the mismatched base. The Sanger tracing of genomic DNA from the same tumor focus is 
overlayed below the RNA-seq reads.
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Figure S2.8 (continued)
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Figure S2.9.  Multiple sequence alignment of the MATH domain of SPOP across species   
Multiple sequence alignment was performed with ClustalW2 and visualized using Jalview.  Residues 
mutated in prostate cancer (Y87, F102, S119, F125, K129, W131, F133, K134) are highlighted. 
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Figure S2.10. Multiple independent siRNAs targeting SPOP have similar effects in prostate cell 
lines 
(A) Expression of SPOP mRNA in DU145 cells transfected with 2 different control siRNAs and 4 different 
SPOP siRNAs, normalized to GAPDH expression, by real-time RT-PCR.   
(B) Quantitation of invaded DU145 cells transfected with control and SPOP siRNAs in Matrigel invasion 
assays.   
(C) Growth curves of DU145 cells transfected with control and SPOP siRNAs, measured with WST-1 
assay.
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Figure S2.11.  Transfection with SPOP siRNA or SPOP mutant does not affect cell growth or 
viability   
(A) Expression of SPOP mRNA in 22Rv1 and DU145 cells transfected with control and SPOP siRNA, 
normalized to GAPDH expression, by real-time RT-PCR.  
(B) Growth curves of 22Rv1 and DU145 cells transfected with control and SPOP siRNA, measured with 
WST-1 assay.  
(C) Western blot showing SPOP expression in DU145 cells transfected with SPOP wild-type and F133V.   
(D) Growth curves of DU145 cells transfected with SPOP wild-type and F133V, measured with WST-1 
assay. 
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Figure S2.12. SPOP is not upregulated in prostate cancer.   
(A) SPOP mRNA expression measured by RNA-seq in 6 benign prostate samples and 53 prostate 
cancers (7 SPOP mutant, 46 SPOP wild-type).  Relative expression is displayed as reads per kilobase 
per million mapped reads (RPKM).   
(B-C) SPOP mRNA expression from a publicly available dataset (www.cbioportal.org/cgx/)12 in 150 
primary prostate cancers (B) and 19 metastases (C). Relative expression is displayed as Z-score versus 
matched normal; positive = increased expression, negative = decreased expression. 
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Figure S2.13.  Tumors with SPOP mutation lack ETS rearrangements 
Relationship of SPOP mutation and ERG rearrangement.  ERG rearrangement was determined by FISH 
and IHC.  
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Figure S2.14. Separate foci of prostate adenocarcinoma with mutually exclusive ERG-rearranged 
and SPOP-mutated status  
(A) Low power view of two distinct foci 
of prostate adenocarcinoma in a 
prostatectomy specimen (H&E stained 
slide of frozen tissue, original 
magnification 2x).   
(B) The tumor on the left side (blue 
box) has Gleason score 3+4=7, is 
ERG-negative by 
immunohistochemistry (D) without 
ERG rearrangement by FISH (inset), 
and demonstrates the F133V SPOP-
mutation (F).   
(C) The tumor on the right side 
(orange box) has Gleason score 
3+3=6, is ERG-positive by 
immunohistochemistry (E) with ERG-
rearrangement by FISH (inset), and 
demonstrates SPOP wild-type 
sequence (G). 
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Figure S2.15. Detection of SPOP mutation in high-grade prostatic intraepithelial neoplasia (HGPIN) 
(A) Low power view of prostate adenocarcinoma (blue box) and HGPIN (orange box) in a prostatectomy 
specimen.  
(B-G) Cancer area before (B) and after (C) Laser Capture Microdissection (LCM). Images of HGPIN 
before (E) and after (F) LCM. DNA sequence demonstrates F133V SPOP-mutation in both 
adenocarcinoma (D) and HGPIN (G).  
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Figure S2.16. Tumors with SPOP mutation lack PTEN deletion in primary but not metastatic 
prostate cancer  
(A) Relationship of SPOP mutation and PTEN deletion determined by FISH in primary prostate cancers 
from the WCMC cohort.   
(B) Relationship of SPOP mutation and PTEN deletion determined by CGH in prostate cancer 
metastases from the UW cohort.  
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Figure S2.17. Ethnicity analysis of exome-sequenced DNA  
Principal component analysis was performed to assess the origin of the study individuals using SNP array 
data. HapMap Phase II samples representing three distinct populations, European (CEU) (red), Yoruban 
(YRI) (blue) and Chinese/Japanese (CHB/JPT) (green), were included in the analysis. The study 
identifiers of the exome-sequenced individuals whose genetic profiles deviate from the CEU pattern are 
shown. 
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Figure S3.1. Recurrent rearrangements alter known and putative prostate cancer genes 
(A) Schematic of CRKL-MAPK1 and NRF1-BRAF fusions detected by WGS, along with validation by 
FISH assay.  
(B) Protein-Protein Interaction (PPI) data were analyzed to nominate rearrangements of potential 
biological consequence. The centrality in a PPI network (Szklarczyk et al., 2011) was assessed for 
protein products of genes that were rearranged in more than one sample (total 397). X- and Y-axes 
measure two indexes of centrality, where larger values indicate more central network positions. Circle 
color and size are proportional to the frequency of gene rearrangement across the tumor cohort. Genes 
scoring in the 95th percentile are depicted as filled circles. The two panels on the right show the centrality 
of recurrently rearranged genes (depicted as red circles in the bottom plot) compared to the entire PPI 
dataset. 
(C) Disruptive genomic rearrangement of JAK1, JAK2 and GSK3B. Dotted lines show intragenic 
breakpoints and corresponding text indicates the locus to which the breakpoint is fused (IGR; inter-genic 
region). Rearrangements depicted above the gene diagrams occurred in a sense-preserving orientation; 
rearrangements below gene diagrams occurred in an anti-sense orientation. Right, genomic 
rearrangements were validated by FISH.  
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Figure S3.1 (continued) 
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Figure S3.2. Signatures of coordinately generated rearrangement chains 
(A) Percentage of DNA deletions bounded by fusion breakpoints that were uniquely identified as deletion 
bridges (blue) or simple deletions (white) in prostate tumors with ten or more deletions in either category.  
(B) Probabilistic model of independent rearrangements across the genome. The expected distribution of 
independent DNA breaks in a given tumor (ρ) is estimated by counting the number of tumors with one or 
more rearrangements within 1Mb tiling windows across the genome. ρ is used to calculate the value of 
µlocal used by ChainFinder in the null model of independent breakpoints. 
(C) Quantile-quantile (Q-Q) plot comparing the distribution of PXY values (the adjacency probabilities for 
independent breakpoints) for observed, simulated and scrambled rearrangements. 
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Figure S3.3. ChainFinder analysis of cancer genomes 
(A) ChainFinder creates a graph representation of somatic rearrangement breakpoints and corresponding 
deletions (see Methods for an extended explanation). (1) Breakpoints of somatic fusions are represented 
as nodes connected by edges. (2) The adjacency probability (PXY) is calculated for pairs of neighboring 
breakpoints based on their reference genome distance (L) and the local rate of rearrangements (µlocal). (3) 
Breakpoints at either boundary of a deletion bridge are joined by edges. (4) The graph is searched for 
cycles connecting breakpoints that are unlikely to have arisen independently, based on PXY values of 
corresponding intervals. (5) The final graph contains sets of rearrangements and associated deletions 
that are unlikely to have occurred independently.  
(B) For a hypothetical cycle involving three rearrangements, the independent breakpoint model 
constitutes all scenarios by which any rearrangement could have arisen independently of others in the 
cycle (see Methods). 
(C-D) Circos plots of rearrangements color-coded by chain for 57 prostate tumors and 59 previously 
sequenced cancer genomes (see Table S3.5B for references). Rearrangements in gray were not 
assigned to a chain. Copy number alteration is shown in blue (deletion) and red (amplification) in the 
inner ring of each plot. 
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Figure S3.3, continued 
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Figure S3.4. Rearrangement profiles of prostate tumor genomes  
(A) Chromoplexy arises in physically interacting chromatin. Chains are enriched for rearrangements that 
fuse portions of the genome in close physical proximity as determined by Hi-C analysis of the RWPE-1 
prostate epithelial cell line (Rickman et al., 2012). See Methods for further details. 
(B) Enrichment of rearrangement breakpoints near to and distant from various genomic features, 
including ChIP-seq peaks from ERG+ VCaP prostate cancer cells (Yu et al., 2010). Color hue reflects the 
degree of enrichment (red) or depletion (blue) and box area reflects statistical significance. “Near” and 
“Far” correspond to within 100kb and further than 1Mb, respectively. The number of rearrangements for 
each tumor is depicted in the gray columns (see Methods). 
(C) Recurrent somatic copy number alterations (SCNAs) across an extended panel of 199 prostate 
tumors grouped by CHD1 deletion status. For comparison, the same samples are also grouped by TP53 
deletion status. 
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Figure S3.4 (continued) 
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Figure S3.5. PCR validation of chained DNA rearrangements 
PCR reactions were run on tumor and normal DNA to amplify across the junctions of 76 somatic fusions. 
Rearrangements are numbered as in Table S3C. Please see Table S3C for a list of additional 
rearrangements that were validated by PCR and deep sequencing on the MiSeq platform.  
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Figure S3.6. Estimation of clonality and stromal DNA admixture 
(A) Apparent DNA admixture computed from WGS and MiSeq deep-sequencing data for 18 somatically 
deleted genes in 7 samples. Error bars for WGS estimations are computed according to Table S6A. 
Clonality calls on WGS data were made with a minimum of 20 informative hemizygous SNPs covered to 
an average depth of 20x or greater. MiSeq calls are based on 4 SNPs with average local coverage of 
>65,000x. The contingency table (bottom-right) shows the agreement for clonality and sub-clonality calls 
between MiSeq and WGS based data (Cochran test, p-value = 1). 
(B) Clonal status of deletions at 14 loci inferred across 49 prostate cancers. The central panel denotes 
the clonal status of a gene lesion in a sample. Empty dark gray rectangles indicate either that the gene 
was not deleted or that there were insufficient informative SNPs to determine clonality status. White 
circles indicate a 100% clonal deletion. Colored circles indicate sub-clonal deletions, where darker color 
indicates a more subclonal deletion. Top rows report Gleason scores, ranging from 6 (light blue) to 9 
(violet), and global stromal DNA admixture, where darker color signifies more admixture. Green bars 
summarize lesion clonality on a per-sample and per-gene basis. Dark and light green denote the 
proportion of clonal and sub-clonal deletions, respectively.  
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Figure S3.6, continued 
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Figure S3.7. Chromoplexy continues during outgrowth of tumor sub-clones and may generate 
multiple rearrangements in closed chains at once 
(A) Three examples of subclonal chains identified by clonality analysis of deletion bridges. Allelic fraction 
distributions of heterozygous SNPs within the deleted segments are indicated. On the right, a clonal 
deletion bridge from the same sample is shown for comparison. 
(B) Closed chains of non-independent rearrangements could arise from (1) a series of balanced 
translocations over multiple cell generations (the “sequential-dependent model”) or (2) concerted 
rearrangements within one cell cycle (the “simultaneous model”). 
(C) For closed chains of rearrangements, bars indicate the median number of sequential balanced 
translocations required to close a chain under the sequential-dependent model (assuming translocations 
occur randomly between breakpoints within the chain). Average values from 10,000 simulations per chain 
size are shown in blue. Red bars indicate the number of rearrangements that disrupt a previously formed 
fusion junction.  
(D) For 121 observed closed chains, the values from (C) and genomic distances between chain 
breakpoints were used to calculate the local rate of rearrangements required to close the chain under the 
sequential-dependent model. This density is compared to the maximum density of rearrangements 
observed in the tumor containing the chain (assessed in 10kb windows genome-wide).  
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